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( 57 ) ABSTRACT 
In some embodiments , the present invention provides com 
positions that comprise : ( 1 ) a biodegradable polymer matrix ; 
and ( 2 ) at least one biodegradable reinforcing particle that is 
dispersed in the matrix . In some embodiments , the biode 
gradable reinforcing particle is selected from the group 
consisting of porous oxide particles and porous semicon 
ductor particles . In additional embodiments , the composi 
tions of the present invention further comprise a ( 3 ) porogen 
particle that is also dispersed in the matrix . In further 
embodiments , the compositions of the present invention are 
also associated with one or more active agents . In various 
embodiments , the active agents are associated with the 
biodegradable polymer matrix , the biodegradable reinforc 
ing particle , and / or the porogen particle . In various embodi 
ments , the compositions of the present invention may be 
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utilized as scaffolds , such as scaffolds for treating bone 
defects . Further embodiments of the present invention per 
tain to methods of making the compositions of the present 
invention . 
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BIODEGRADABLE SCAFFOLDS defect in the subject a scaffold of the present invention . 
Further embodiments of the present invention pertain to 
CROSS - REFERENCE TO RELATED methods of making the compositions of the present inven 
APPLICATIONS tion . 
5 The methods and compositions of the present invention 
This application is a continuation of U . S . application Ser . have numerous applications and advantages . For instance , in 
No . 13 / 809 , 291 , filed Mar . 22 , 2013 , which claims priority various embodiments , the compositions and methods of the 
to U . S . Provisional Patent Application No . 61 / 363 , 835 , filed present invention may be used in the treatment of bone 
on Jul . 13 , 2010 and U . S . Provisional Patent Application No . defects , wound healing , tissue engineering , and the preven 
61 / 363 , 126 , filed on Jul . 9 , 2010 . The entirety of each of the 10 tion or treatment of microbial infections . 
above - identified applications are incorporated herein by 
reference . BRIEF DESCRIPTION OF THE FIGURES 
STATEMENT REGARDING FEDERALLY In order that the manner in which the above recited and 
SPONSORED RESEARCH 15 other advantages and objects of the invention are obtained , 
a more particular description of the invention briefly 
This invention was made with government support under described above will be rendered by reference to specific 
DARPA Grant No . W911NF - 09 - 1 - 0044 , awarded by the embodiments thereof , which are illustrated in the appended 
U . S . Department of Defense . The government has certain Figures . Understanding that these Figures depict only typi 
rights in the invention . 20 cal embodiments of the invention and are therefore not to be 
considered limiting of its scope , the invention will be 
BACKGROUND OF THE INVENTION described with additional specificity and detail through the 
use of the accompanying Figures in which : 
Current compositions and methods for tissue engineering FIGS . 1A - 1F present images of alginate hydrogel micro 
or wound healing through the use of scaffolds suffer from 25 spheres / beads ( ~ 200 - 500 microns ) . Inside the beads is plate 
various limitations . Such limitations may include insuffi - let - rich plasma ( PRP ) as well as mesenchymal stem cells 
cient biocompatibility , insufficient biodegradability , lack of ( FIGS . 1A - 1B : optical image ; FIG . 1C : confocal image 
mechanical stability , and insufficient porosity for the deliv - green - cells ; FIGS . 1D - 1F are scanning electron micros 
ery of active agents . Therefore , there is currently a need to copy ( SEM ) images ) . 
develop new methods and compositions for tissue engineer - 30 FIG . 2 shows poly ( lactic - co - glycolic acid ) ( PLGA ) 
ing and wound healing that address the aforementioned coated mesoporous silicon . 
limitations . FIGS . 3A - 3D show images of surface - modified and co 
condensated silica nanorods SEM ( FIGS . 3A - 3B ) at two 
BRIEF SUMMARY OF THE INVENTION different magnifications and transmission electron micro 
35 scope ( TEM ) ( FIG . 3C - 3D ) at two different magnifications . 
In some embodiments , the present invention provides FIG . 4 illustrates the injectability of poly ( propylene 
compositions that comprise : ( 1 ) a biodegradable polymer fumarate ) ( PPF ) . 
matrix ( e . g . , an unsaturated biodegradable polymer , such as FIG . 5 is a photograph of an alginate / PPF composite 
poly ( propylene fumarate ) ( PPF ) ) ; and ( 2 ) at least one bio - scaffold fabricated using a cylindrical Teflon mold . 
degradable reinforcing particle that is dispersed in the 40 FIGS . 6A - 6F illustrate the operation of a biodegradable 
matrix . In some embodiments , the biodegradable reinforcing scaffold to treat a bone defect . 
particle is selected from the group consisting of porous FIG . 6A shows the integration of matrix components . 
oxide particles and porous semiconductor particles ( e . g . , FIG . 6B shows the injection of the bioactive matrix into 
mesoporous silica particles ) . In additional embodiments , the the bone defect ; 
compositions of the present invention further comprise a ( 3 ) 45 FIG . 6C shows the area of the bone defect 1 week after 
porogen particle that is also dispersed in the matrix . In injection . Degradation of alginate porogens and delivery of 
various embodiments , such porogen particles may be hydro - cells and SEs to the surrounding scaffold can be seen . 
gels ( e . g . , alginates , fibrins , and gelatins ) , natural or syn - FIG . 6D shows the area of the bone defect 2 weeks after 
thetic biodegradable particles , biodegradable porous par injection . Degradation of silicon enclosures ( SES ) and 
ticles ( e . g . , silicon porous particles ) , and biocompatible 50 microparticles or nanoparticles ( MSNS ) and initial vascu 
vesicles ( e . g . , liposomes and / or micelles ) . larization can be seen . 
In further embodiments , the compositions of the present FIG . 6E shows the area of the defect 3 weeks after 
invention are associated with one or more active agents . In injection . Woven bone formation can be seen . 
various embodiments , the active agents are associated with FIG . 6F shows a remodeled bone that is formed after the 
the biodegradable polymer matrix , the biodegradable rein - 55 completion of treatment . 
forcing particle , and / or the porogen particle . In some FIGS . 7A - 7F show various experimental results and 
embodiments , the active agent comprises therapeutics , anti - schemes related to calcium alginate bead production . 
biotics , proteins , platelet rich plasma ( PRP ) , cells ( e . g . , stem FIGS . 7A - 7B show calcium alginate beads produced 
cells ) , degradation inducers of porogen particles ( e . g . , lactic without PRP ( FIG . 7A ) , or with PRP ( FIG . 7B ) . 
acid and / or sodium citrate ) , anti - inflammatory agents , cell 60 FIGS . 7C - 7E depict a scheme for production of calcium 
viability enhancing agents ( e . g . , glucose ) , and / or imaging alginate beads by an internal gelation / emulsion technique . 
agents ( e . g . , barium sulfate ) . Insoluble calcium complex is dispersed in the aqueous phase 
In various embodiments , the compositions of the present containing sodium alginate and bioactive components ( FIG . 
invention may be utilized as scaffolds , such as scaffolds for 7C ) . The aqueous phase is added to the oil phase with a 
treating bone defects . Accordingly , in some embodiments , 65 surfactant present . Continuous stirring forms a stable emul 
the present invention also pertains to methods of treating a sion ( FIG . 7D ) . An oil soluble acid is then added to the 
bone defect in a subject by applying to an area of the bone mixture , thereby reducing the pH and triggering the release 
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of calcium ions from the calcium complex to initiate gela FIGS . 19A - 19B present Brunauer - Emmett - Teller ( BET ) 
tion of the formed microspheres ( FIG . 7E ) . data showing the pore size distribution of silica nanorods to 
FIG . 7F shows the size distribution of the formed calcium be around 2 . 56 nm . 
alginate beads . The peak size is in the range of 250 to 400 FIGS . 20A - 20C demonstrate biocompatibility of mesopo 
microns . 5 rous silica . 
FIGS . 8A - 8B show elastic modulus ( FIG . 8A ) and stress FIG . 20A shows high cell viability after 24 hours of 
( FIG . 8B ) at offset yield of composite putty containing 40 % treatment with silica concentrations of about 0 . 01 % by 
alginate porogens and porous PPF scaffolds . The results are weight . The silica used in this experiment are washed E ( post 
compared to native human trabecular bone . modified ) and washed CC ( co - condensated ) . 
FIG . 9 presents a temperature profile of PPF cross - linking 10 FIG . 20B shows viable cell count of MDA231 cells 
with varying amounts of alginate porogens . incubated with mesoporous nanorods ( MSNRs ) . The cells 
FIGS . 10A - 100 show various studies relating to the are stained with Annexin V , which is indicative of apoptosis . 
physiological effects of alginate porogens . FIG . 20C shows MTT assays of human umbilical vein 
FIGS . 10A - 10B show PDGF ( platelet - derived growth endothelial cells ( HUVEC ) incubated with MSNRs .
factor ) , VEGF ( vascular endothelial growth factor ) ( FIG . 15 FIG . 21 shows an X - ray image of agarose composites 
10C ) , and RANTES ( Regulated on Activation , Normal T with different concentrations of silica nanorods containing 
Expressed and Secreted ) ( FIG . 10D ) , release from PRP barium sulfate ( from right to left : 0 % , 0 . 5 % and 2 % ) . 
within alginate porogens of varying sizes . FIG . 22 shows GIF images through TEM showing the 
FIG . 10E shows the effects of PRP released from PRP presence of barium and sulfur within silica nanorods . 
loaded alginate porogens on cell proliferation over a three 20 FIG . 23 is a graph demonstrating controlled release of a 
day period . model drug , DOX - HC1 , from silica nanorods . 
FIG . 10F shows the effects of PRP release from PRP FIG . 24 is a graph demonstrating controlled release of 
loaded alginate porogens on cell migration . DAPI stained Cefazolin from silica nanorods . 
cells that migrated through an 8 micron transwell towards FIGS . 25A - 25B show various data related to the mechani 
the released chemokines are shown on the top panel . Cell 25 cal strength of silica nanorods . 
hemacytometer count of cells that migrated through the 8 FIG . 25A shows the stress offset of control , 2 . 5 % co 
micron transwell over the period of 4 days is illustrated in condensated silica nanorods ( CC ) and post - modified silica 
the graph on the bottom panel . ( E ) 
FIG . 10G shows subcutaneous implantation of calcium FIG . 25B shows the compressive modulus of 2 . 5 % co 
alginate porogens clotted in a fibrin matrix in rats , vascu - 30 condensated silica nanorods ( CC ) and post - modified silica 
larization of the scaffold at 2 weeks ( FIGS . 10H - I ) , H & E when dispersed in PPF polymer . 
stain ( FIG . 10J ) , and Goldner Trichrome stain ( FIG . 10K ) of FIGS . 26A - 26C show data relating to the mineralization 
histological section from the scaffold . The results indicate of various scaffolds , and the use of PPF in various compo 
vessel formation and premature collagen formation ( green ) . sitions . 
FIG . 10L shows viability staining of stem cells cryo - 35 FIG . 26A shows data relating to the mineralization of 
freezed in alginate porogens after thawing . Live cells are agarose - coated silica nanoparticle scaffolds . 
shown in green , and dead cells are shown in red . The bottom FIG . 26B shows images from a mineralization study with 
panel shows a trypan blue exclusion count of viable cells Rat Compact Bone stromal cells after 3 weeks . 
after cryopreservation and thawing ( FIG . 10M ) . From left to right the first panel shows a phase image of 
FIG . 10N shows calcium alginate accelerated degradation 40 matrigel alone in osteogenic media ; 
using sodium citrate as a chelation agent at various concen - the second panel shows a phase image of matrigel and 
trations ( top panel ) . Cytotoxicity of Alginate / PRP porogens mSNR in osteogenic media ; and 
from the top panel on rat cortical bone mesenchymal cells the third panel shows a phase image of matrigel and 
( MSC ) are shown on the bottom panel ( FIG . 100 ) . mSNR , in osteogenic media . The sample was stained with 
FIGS . 11A - 11C demonstrate an increase in aspect ratio 45 Von Kossa stain for calcium - phosphate mineral ( brown ) and 
and a decrease in the size of alginate porogen beads through alkaline phosphatase enzyme activity ( blue ) . The sample 
the adjustment of tetraethyl orthosilicate ( TEOS ) ( FIG . was also stained with the nuclear counterstain , nuclear fast 
11A ) , cetyl trimethyl ammonium bromide ( CTAB ) ( FIG . red ( pink ) . 
11B ) , and ammonia ( FIG . 11C ) . FIG . 26C shows temperature increase due to PPF inject 
FIG . 12 presents results of measuring zeta potential for 50 able putty cross - linking . 
co - condensated acrylate nanorods showing a surface charge FIG . 27 shows cefazolin release from gelatin - coated mes 
of around - 17 mV . Oxidized silica ( unmodified ) has a oporous silicon ( MPS ) . 
surface charge of around - 40 mV . FIG . 28 shows cefazolin release from agarose coated 
FIG . 13 presents Fourier transform infrared spectrum MPS . 
( FTIR ) for post - modified acrylate nanorods showing C = 0 55 FIG . 29 shows cefazolin release from APTES coated 
peaks at 1716 cm - 1 and C = C peaks at 1621 cm - ? . MPS . 
FIGS . 14 - 16 show silica nanorods with 2 . 5 % trimethox - FIGS . 30A - 30C show results from the flow cytometry 
ysilyl propyl methacrylate ( FIG . 14 ) ; 5 % trimethoxysilyl analysis of MPS ( FIG . 30A : 2000xg rcf ; FIG . 30B : 10000xg 
propyl methacrylate ( FIG . 15 ) ; and 10 % trimethoxysilyl rcf ; FIG . 30C : 26000xg rcf ) . Data are from one experiment 
propyl methacrylate ( FIG . 16 ) . 60 representative of three . SSC : side scatter ; FSC : forward 
FIG . 17 presents results of measuring zeta potential for scatter . 
co - condensated acrylate particles showing a surface charge FIG . 31 shows results from multisizer analysis of the 
of around - 17 mV . Oxidized silica ( unmodified ) has a MPS . 
surface charge of around - 40 mV . FIG . 32 presents results of FACS analysis of geometric 
FIG . 18 presents an FTIR for post modified acrylate 65 mean X value of MPS Size Distribution . 
nanorods showing C30 peaks at 1716 cm - l and C = C FIG . 33 presents results of FACS analysis of geometric 
peaks at 1621 cm - . mean Y value of MPS Size Distribution . 
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FIGS . 34A - 34B presents zeta potential of different sur FIGS . 43A - 43F show confocal study of cellular uptake of 
face modified MPS . protein from internalized particles ( NSP ) : HUVEC incu 
FIGS . 35A - 35J show agarose modification of nanoporous bated for ( FIG . 43A , FIG . 43C , respectively ) 24 hours and 
silicon particles ( NSP ) : NSP observed with SEM at low ( FIG . 43B , FIG . 43D respectively ) 48 hours with ( FIG . 43A , 
( FIGS . 35A - 35E ) and high ( FIGS . 35F - 35J ) magnification : 5 FIG . 43B ) FITC - BSA loaded agarose coated NSP , ( 43C , 
( a and A ) bare NSP and ( b , c , d and e ) agarose coated NSP 43D ) FITC - BSA loaded not coated NSP . Scale bar is 10 um . 
with different agarose concentration ( 0 . 05 , 0 . 125 , 0 . 25 and FIG . 43E and FIG . 43F show quantification of uptake of 
0 . 5 % respectively ) . BSA within the cells : fluorescence intensity within ( FIG . 43E ) the nucleus and ( FIG . 43B ) the cytoplasm of the cells FIGS . 36A - 36H show silicon particles ( NSP ) degrada 
tion : SEM observation at different times of NSP : bare NSP D 10 quantified with NIS - Elements . Red square and blue triangle refer to NC and Ag NSP , respectively . after ( FIG . 36A ) 2 hours , ( FIG . 36B ) 4 hours , ( FIG . 36C ) 8 FIGS . 44A - 44D are schematic diagrams of PLGA / pSi hours , ( FIG . 36D ) 12 hours , ( FIG . 36E ) 1 day , ( FIG . 36F ) 2 microspheres fabrication through the S / O / W emulsion days , ( FIG . 36G ) 3 days , and ( FIG . 36H ) 4 days of incuba method . ( FIG . 44A ) PLGA / PSi suspension was poured into tion with PBS . Scale bar is 1 um . 15 water phase . ( FIG . 44B ) The suspension was emulsified in 
FIGS . 37A - 37P show particles degradation as measured the water phase . ( FIG . 44C ) Surfactants were added to 
through FACS : ( FIGS . 37A , 370 , 37H , and 37K ) Forward stabilize the structures . ( FIG . 44D ) Cartoon depicting the 
and side scattering data analysis for bare ( NC ) compared final composition of a PLGA / pSi microsphere ( components 
with nanoporous silicon particles coated two agarose con - not in scale ) . 
centrations ( 0 . 05 % agarose concentration ( A1 ) ( FIG . 37B , 20 FIGS . 45A - 45D show an SEM image of pSi particles at : 
FIG . 37E , FIG . 371 , and FIG . 37L ) and 0 . 125 % agarose ( FIG . 45A ) lower magnification showing particle uniformity 
concentration ( A2 ) ( FIG . 37C , FIG . 37F , FIG . 37 ) , and FIG . in size and shape ; and ( FIG . 45B ) a higher magnification 
37M ) , over time ( 1 h - 72 h ) ; ( FIG . 370 ) size measurements micrograph revealing the pore structure as seen on the 
over time of bare ( NC ) and agarose coated nanoporous surface of the particle . Low power micrographs illustrate : 
silicon particles with two agarose concentrations ( 0 . 05 % and 25 ( FIG . 45C ) the front ; and ( FIG . 45D ) rear surfaces of a pSi 
0 . 125 % , A1 and A2 respectively ) ; and ( FIG . 37P ) shows the particle . 
correlation . FIGS . 46A - 46D show a physical characterization and size 
FIGS . 38A - 38C show protein load and release : ( FIG . distribution of PLGA / PSi microspheres . ( FIG . 46A ) SEM 
38A ) amount of BSA loaded in bare ( NC ) and agarose image of presorted microspheres . ( FIG . 46B ) An optical 
coated particles with two agarose concentrations ( 0 . 125 and 30 microscopy image shows the presence of pSi particles 
0 . 05 % , A1 and A2 , respectively ) ; ( FIG . 38B ) fluorescence of ( arrows ) enclosed in the larger PLGA spheres . ( FIG . 46C ) 
agarose coated ( A1 and A2 ) and NC nanoporous silicon Fluorescence microscope , and ( FIG . 46D ) the size distribu 
particles ( NSP ) , as measured by FACS , and ( FIG . 38C ) BSA tion of PLGA / pSi microspheres displays the uniform prod 
released from agarose coated ( A1 and A2 ) and NC NPS , as uct centered around 24 . 5 um . 
measured with spectrofluorimetry . 35 FIGS . 47A - 47E show a FACS analysis of nonsorted and 
FIGS . 39A - 39D show gel electrophoresis : ( FIG . 39A ) sorted PLGA / pSi microspheres prepared with 488 - DyLight 
SDS - page of protein solution released after 24 hours from conjugated pSi particles ( DyLight - PLGA / PSi micro 
bare ( NC ) and agarose coated ( Ag ) nanoporous silicon spheres ) : ( FIG . 47A ) the percent of DyLight - PLGA / pSi 
particles treated for different times with trypsin ( treatment microspheres in the non - sorted , sorted microspheres and 
duration in minutes , printed in white on each column ) 1 , 2 40 supernatant ; ( FIG . 47B ) the mean fluorescence of the sorted , 
and 3 indicate the most abundant digestion products . ( FIG . nonsorted microspheres , and the supernatant ; ( FIG . 47C ) 
39B , FIG . 39C , FIG . 39D ) SDS - page relative intensity fluorescence intensity and distribution of 488 - DyLight con 
quantification with Image of trypsin ( Tryp ) , BSA and the jugated pSi particles ( light green ) , nonsorted microspheres 
three most abundant digestion products ( Dig . 1 , 2 and 3 ) ( blue ) , sorted microspheres ( dark green ) , and supernatant 
detected in the protein solution released after 24 hours from 45 solution ( black ) . Also shown are confocal images of ( FIG . 
bare ( NC ) and agarose coated ( Ag composition 0 . 125 % ) 47D ) nonsorted microspheres and ( FIG . 47E ) sorted micro 
silicon particles after different trypsin treatment duration spheres . 
FIGS . 40A - 40B show released protein solution chroma - FIGS . 48A - 48D show release profiles of FITC - BSA from 
tography through high pressure liquid chromatography various examined PLGA / pSi microsphere formulations , 
( HPLC ) analysis of BSA solution released after 24 hours by 50 including : ( FIG . 48A ) total FITC - BSA released over 27 
( FIG . 40A ) NC and ( FIG . 40B ) Ag particles not treated days ; ( FIG . 48B ) first three day release ; ( FIG . 48C ) day 5 to 
( blue - 1 ) and treated with trypsin for 15 minutes , 2 hours , 4 15 release ; and ( FIG . 48D ) day 15 to 27 release . 
hours , 8 hours and 18 hours ( green - 2 , light blue - 3 , brown - 4 , FIGS . 49 A - 49B show PLGA and PLGA / pSi microspheres 
light green - 5 and pink - 6 , respectively ) . Arrows point to three analyzed via FACS during in vitro release . 
digestion products , the amount of which increases with 55 FIG . 49 A shows histographic overlay of the fluorescence 
trypsin treatment time . intensity and distribution of control PLGA ( left ) and PLGAI 
FIGS . 41A - 41F show in vitro confocal study of cellular pSi ( right ) over 2 weeks of incubation in PBS . 
internalization of silicon particles ( NSP ) and protein uptake : FIG . 49B shows decrease of fluorescence intensity as 
( FIG . 41A - control ) cells ( HUVEC ) incubated for 48 hours measured through FACS dropped to minimum at day 3 in 
without NSP ; ( FIG . 41B ) with BSA loaded NSP added into 60 control PLGA . PLGA / pSi showed slow decrease in fluores 
the media ; ( FIG . 41C ) with agarose coated BSA loaded cence intensity and displayed 3 fold the intensity of control 
NSEs added into the media ; ( FIG . 41D ) with NC and ( FIG . at 2 weeks . 
41E ) Ag BSA loaded NSP placed in a transwell on top of the FIGS . 50A - 50H and FIGS . 50J - 50P show SEM images of 
cells , or ( FIG . 41F ) in BSA solution . White scale bar is 50 PLGA / pSi microsphere degradation over 1 , 2 , 3 , 4 , and 6 
um in FIG . 41A - 41C and 10 um in FIG . 41D - 41F . 65 weeks with 6 % coating ( FIGS . 50A - 50E ) , 10 % coating 
FIG . 42 shows pH measurement of acid solution change ( FIGS . 50F - 50H and FIGS . 50J - 50K ) , or 20 % coating 
due to agarose coating solution . ( FIGS . 50L - 50P ) . 
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FIGS . 51A - 51B show the pH of pSi , PLGA , and PLGA term “ including " , as well as other forms , such as “ includes ” 
pSi microsphere degradation byproducts in PBS at 37° C . and “ included ” , is not limiting . Also , terms such as “ ele 
over 4 weeks for ( FIG . 51A ) PLGA - only microspheres ment ” or “ component " encompass both elements or com 
( control ) and ( FIG . 51B ) PLGA / pSi microspheres . ponents comprising one unit and elements or components 
FIG . 52 shows FITC - BSA degradation over 2 weeks . 5 that comprise more than one unit unless specifically stated 
SPS - PAGE of release products showed BSA ( approximately otherwise . 
68 kDa ) released from PLGA / pSi microspheres suffered no The section headings used herein are for organizational 
degradation bands compared to controls ( BSA in solution for purposes only and are not to be construed as limiting the 
7 and 14 days , columns 2 and 3 , respectively ) . subject matter described . All documents , or portions of 
FIGS . 53A - 53G show mineralization on the surface of 10 documents , cited in this application , including , but not 
PLGA / pSi microspheres , including SEM images of ( FIG . limited to , patents , patent applications , articles , books , and 
53A , FIG . 53C ) PLGA and ( FIG . 53B , FIG . 53D ) PLGA / pSi treatises , are hereby expressly incorporated herein by refer 
microspheres in osteogenic media after 3 and 21 days , ence in their entirety for any purpose . In the event that one 
respectively . Also shown are ( FIG . 53E - FIG . 53F ) SEM or more of the incorporated literature and similar materials 
images at day 21 at higher magnification . In addition , the 15 defines a term in a manner that contradicts the definition of 
( FIG . 53G ) EDX spectrum of mineralized PLGA / pSi micro - that term in this application , this application controls . 
spheres on day 3 ( gray dot line ) and day 14 ( black solid line ) 
is shown . Definitions 
FIGS . 54A - 54J show confocal microscopy images of 
PLGA / pSi microparticles ( loaded with green fluorescent 20 Unless otherwise specified “ a ” or “ an ” means one or 
BSA ) were not internalized by bone marrow derived stromal more . 
cells ( BMSCs ) at ( FIGS . 54D - 54G ) O hour , ( FIGS . 54E - “ Microparticle ” means a particle having a maximum 
54H ) 48 hours , or ( FIGS . 54F - 541 ) 120 hours , while ( FIG . characteristic size from 1 micron to 1000 microns , or from 
54G ) pSi microparticles were internalized by BMSCs at 0 . 5 1 micron to 100 microns . 
hours ( FIG . 54A ) , 48 hours ( FIG . 54B ) , and 120 hours ( FIG . 25 “ Nanoparticle ” means a particle having a maximum char 
54C ) . acteristic size of less than 1 micron . 
FIG . 54J shows a schematic diagram of the mechanism of “ Nanoporous ” or “ nanopores ” refers to pores with an 
action of PLGA / pSi microspheres compared to pSi . Follow average size of less than 1 micron . 
ing internalization , pSi is trapped within lysosomes , while “ Biodegradable material ” refers to a material that can 
the PLGA / pSi particles are not endocytosed by BMSC and 30 dissolve or degrade in a physiological medium , such as PBS 
release their payload outside the cells where it can exert its or serum . 
bioactive function and trigger nuclear changes through the “ Biocompatible ” refers to a material that , when exposed 
classic mechanism of signal cascade . to living cells , will support an appropriate cellular activity of 
FIGS . 55A - 55E show confocal images of stained HUVEC the cells without causing an undesirable effect in the cells 
( green - BSA , red - actine filaments , blue - nuclei ) after 7 days 35 such as a change in a living cycle of the cells ; a release of 
in culture ( FIG . 55A , FIG . 55B - control , BSA in solution ) , proinflammatory factors ; a change in a proliferation rate of 
or after incubation with BSA loaded PLGA / pSi micro the cells and a cytotoxic effect . 
spheres ( FIG . 55C , FIG . 55D ) , with overlap of all three APTES stands for 3 - aminopropyltriethoxysilane . 
fluorescent channels ( FIG . 55A and FIG . 55C ) , or bright Loading capacity or loading efficiency refers to an amount 
field and green channels ( FIG . 55B and FIG . 55D ) . Average 40 of a load that can be contained in pores of a porous object . 
fluorescence intensity of the three fluorescent channels ( FIG . Introduction 
55E ) related to control HUVEC ( dark color bars ) and Insufficient healing occurring in cases of traumatic frac 
HUVEC incubated with PLGA / pSi ( light color bars ) as tures or injuries may be substantial . For instance , severe leg 
measured at the confocal microscope are also shown . injuries are typically repaired with bone grafts . Pins , plates 
FIG . 56 shows an analysis of the porous structure of MP2 45 or screws hold the grafts to healthy bone while external 
porous silicon microparticles by nitrogen adsorption - des - fixation provides support . However , it may take months to 
orption isotherms at 77K . The inset graph shows pore size years before the injured patient fully recovers . Therefore , a 
distribution according to the Barrett - Joyner - Halenda model . technology that provides both immediate mechanical stabil 
FIG . 57 shows Zeta potential analysis indicating that the ity to restore function and accelerates the regeneration 
oxidized pSi surface had a surface charge of - 30 . 39 My ( left 50 process is needed . 
panel ) , while the APTES modified pSi particles had a value The ideal tissue engineering scaffold may require several 
of 6 . 44 mV ( right panel ) . characteristics . Such characteristics may include biocompat 
FIG . 58 shows the loading efficiency of seven different ibility , biodegradability , mechanical stability , interconnected 
types of pSi particles . For a certain concentration of FITC porosity and the ability to deliver active agents , such as 
BSA solution , mesoporous silicon particles has the highest 55 therapeutic and / or imaging agents . To achieve such proper 
loading efficiency . ties , one may combine diverse technologies into a multi 
functional composite materials . For instance , it is well 
DETAILED DESCRIPTION OF EXEMPLARY known in the field of tissue engineering ( TE ) that the 
EMBODIMENTS porosity and pore interconnectivity of the scaffold may be 
60 essential for tissue in - growth , vascularization and nutrient 
It is to be understood that both the foregoing general supply . However , high porosity may severely compromise 
description and the following detailed description are exem - mechanical properties . The challenge may lie in the trade - off 
plary and explanatory only , and are not restrictive of the between porosity and mechanical integrity , wherein porosity 
invention , as claimed . In this application , the use of the is usually negatively correlated with mechanic al strength . 
singular includes the plural , the word “ a ” or “ an ” means “ at 65 The present disclosure presents a strategy for conquering 
least one ” , and the use of “ or ” means " and / or ” , unless the challenge of meeting mechanical requirements of tissue 
specifically stated otherwise . Furthermore , the use of the engineering scaffolds while maintaining the porous structure 
tion . 
US 10 , 058 , 633 B2 
10 
necessary for tissue integration and supplying of essential invention may be further amplified by the use of biodegrad 
bioactive molecules for accelerated tissue regeneration . In able reinforcing particles , porogen particles and active 
some embodiments , the present invention provides compo - agents . 
sitions that comprise : ( 1 ) a biodegradable polymer matrix ; Biodegradable Reinforcing Particles 
and ( 2 ) at least one biodegradable reinforcing particle that is 5 In the present invention , biodegradable reinforcing par 
dispersed in the matrix . In additional embodiments , the ticles generally refer to particles of the nano scale that 
compositions of the present invention further comprise a ( 3 ) provide mechanical strength to the surrounding polymer 
porogen particle that is also dispersed in the matrix . In matrix . Biodegradable reinforcing particles may also simul 
further embodiments , one or more of the above - mentioned taneously release active agents upon biodegradation . Gen 
individual components are associated with an active agent . 10 erally , the biodegradable reinforcing particles of the present 
In further embodiments , the compositions of the present invention are dispersed in the biodegradable polymer matrix and selected from the group consisting of porous oxide invention may be utilized as scaffolds , such as scaffolds for particles and porous semiconductor particles . treating bone defects . Accordingly , in various embodiments , A person of ordinary skill in the art will recognize that 
the present invention also provides methods of treating a 15 various suitable biodegradable reinforcing particles may be 
bone defect in a subject by applying to an area of the bone used in the present invention . Non - limiting examples of 
defect in the subject a scaffold of the present invention . suitable biodegradable reinforcing particles include biode 
Further embodiments of the present invention pertain to gradable oxide microparticles or nanoparticles ( e . g . , silica 
methods of making the compositions of the present inven particles ) , or biodegradable semiconductor microparticles or 
20 nanoparticle ( e . g . , silicon particles ) . In many embodiments , 
As discussed in more detail below , the methods and the biodegradable reinforcing particles of the present inven 
compositions of the present invention have numerous appli - tion may comprise porous or mesoporous microparticles or 
cations and advantages . More detailed aspects of various nanoparticles , such as mesoporous silica or silicon particles . 
embodiments of the present invention will now be described In some embodiments , the biodegradable reinforcing par 
below as specific and non - limiting examples . 25 ticles may comprise nanoporous microparticles or nanopar 
Biodegradable Polymer Matrix ticles . 
In the present invention , biodegradable polymer matrices In various embodiments , the biodegradable reinforcing 
generally refer to polymer - based matrices that show at least particles of the present invention may also be associated with an active agent . Non - limiting examples of suitable some biodegradability . In various embodiments , the biode 
gradable polymer matrices of the present invention may 30 30 active agents include degradation inducers of the porogen 
comprise a biodegradable polymer . Non - limiting examples particles , imaging agents ( e . g . , barium sulfate ) , proteins , platelet rich plasma , cell viability enhancing agents ( e . g . , of suitable biodegradable polymers include collagen , gela glucose ) , anti - inflammatory agents , antibiotics , therapeutic tin , alginate , polycaprolactone , and poly ( lactic - co - glycolic agents , growth factors , DNA , siRNA , and the like . Such acid ) ( PLGA ) . 35 active agents may also include : agents that can prevent an In many embodiments , the biodegradable polymer may be infection at a site of a bone defect , such as a bone fracture ; an unsaturated biodegradable polymer ( i . e . a biodegradable agents that can contribute to bone regeneration at a site of a 
polymer containing at least one unsaturated carbon - carbon bone defect ; and agents that can contribute to cell viability 
bond , such as a double or a triple bond ) . Such unsaturated at a site of a bone defect . 
polymers may be cross - linkable in situ . Non - limiting 40 In more specific embodiments , the biodegradable rein 
examples of unsaturated biodegradable polymers include forcing particles of the present invention contain an imaging 
poly ( propylene fumarate ) ( PPF ) , poly ( E - caprolactone - fu - agent , which may facilitate imaging and / or monitoring of a 
marate ) , and mixtures and co - polymers thereof . site of a bone defect , such as a bone fracture . One non 
Additional biodegradable polymers that may be used in limiting example of such an imaging agent may be barium 
the polymer matrices of the present invention are disclosed , 45 sulfate , which may facilitate X - ray imaging of a bone defect 
for example , in WO 2010 / 040188 ; WO2006 / 023130 ; site . 
WO1997 / 045532 ; US2005 / 0177249 ; US2006 / 026335 ; U . S . In more specific embodiments , biodegradable reinforcing 
Pat . Nos . 6 , 858 , 229 , 5 , 522 , 895 , 6 , 281 , 257 , and 6 , 124 , 373 ; particles that comprise porous microparticles or nanopar 
Mano et al . Composites Science and Technology . 2004 . ticles ( reinforcing microparticles or nanoparticles ) may con 
64 : 789 - 817 ; Rezwan et al . Biomaterials . 2006 . 27 : 3413 ; 50 tain one or more active agents , such as therapeutic and / or 
Boccaccini et al . Expert Review of Medical Devices . 2005 . imaging agents that may be released upon the degradation of 
2 ( 3 ) : 303 ; Advanced Drug Delivery Reviews . 2007 . 59 ( 4 - 5 ) : the particles . The active agents which may be contained 
249 ; and Tan et al . Materials . 2010 . 3 : 1746 ; J R Soc . inside the reinforcing microparticles or nanoparticles may 
Interface . 2007 . 4 ( 17 ) : 999 - 1030 . include , without limitation , antibiotics , anti - inflammatory 
As set forth in more detail below , the biodegradable 55 agents , proteins ( such as growth factor ) , and nucleic acids 
polymer matrices of the present invention may be associated ( such as DNA and siRNA ) . In some embodiments , the 
with one or more active agents . Furthermore , the biodegrad - growth factors may include one or more of PDGFaß , 
able polymer matrices of the present invention may be PDGFaa , PDGFBB , TGF1 , TGF2 , vascular endothelial 
associated with biodegradable reinforcing particles and growth factor ( VEGF ) and / or epithelial growth factor 
porogen particles . 60 ( EGF ) . 
In a more specific embodiment , the biodegradable poly - In some embodiments , the reinforcing microparticles or 
mer matrix comprises PPF . By way of background PPF is an nanoparticles may contain one or more proteins , such as 
example of an in situ cross - linkable polymer that exhibits fibrin , fibronectin and vitronectin . In some embodiments , the 
mechanical properties close to the ones of the trabecular reinforcing microparticle or nanoparticle may contain plate 
bone . See , e . g . Peter et al . J Biomed Mater Res . 1999 ; 44 : 65 let - rich plasma ( PRP ) . PRP may contain PDGFaß , 
314 - 21 . As set forth in more detail below , these properties of PDGFaa , PDGFBB , TGF1 , TGF2 , VEGF , EGF , fibrin , 
PPF ' s in the biodegradable polymer matrices of the present fibronectin and / or vitronectin . In some embodiments , the 
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reinforcing microparticles or nanoparticles may contain a The cross - section of the biodegradable reinforcing par 
cell viability enhancing agent , which may be , for example , ticles of the present invention may have a variety of shapes . 
a sugar , such as glucose or glucose derivative , such as In some embodiments , the cross - section may be circular or 
glucose lactam . In some embodiments , the reinforcing elliptical . In some embodiments , the cross - section may be 
microparticles or nanoparticles may contain a bone loss 5 rectangular . Considerations for selecting shapes and sizes of 
preventing agent , which may be , for example , a biphospho reinforcing particles are disclosed , for example , in Rangana 
nate , such as etidronate , clodronate , tiludronate , pamidro than et al . Acta Biometer . 2010 . 6 ( 9 ) : 3448 - 56 . Epub 2010 
nate , neridronate , olpadronate , alendronate , ibandronate , Mar . 24 . 
risendronate , or zolendronate . In many embodiment , the biodegradable reinforcing par 
In some embodiments , the reinforcing microparticles or . 10 ticles may be integrated in the biodegradable polymer matrix . Such integration may be involve covalently binding nanoparticles may contain one or more imaging agents , the reinforcing particles with the polymer matrix . For such which may used for imaging or monitoring the treated bone covalent binding , the reinforcing particles may comprise a defect site . Such imaging agents may include , but not be chemical moiety that is capable of covalently bonding to the 
limited to X - ray contrast agents , such as barium sulfate ; 15 biodegradable polymer . One non - limiting example of such a 
MRI contrast agents ; ultrasound contrast agents ; fluorescent chemical moiety may be an acrylate . In some embodiments , 
agents , such as fluorescent dyes and quantum dots ; and the chemical moiety may be introduced on a surface of the 
metal nanoparticles . In more specific embodiments , the biodegradable reinforcing particles after the particles are 
reinforcing microparticle or nanoparticle is a mesoporous fabricated or synthesized . Yet , in some other embodiments , 
silica particle , and the active agent is an imaging agent that 20 the chemical moiety may be introduced into the biodegrad 
is embedded into the matrix of the silica particle . able reinforcing particles during their fabrication or synthe 
In various embodiments , the biodegradable reinforcing sis . 
particles may constitute from 1 % to 30 % , from 2 % to 25 % , Porogen Particles 
from 3 % to 20 % , or from 5 % to 15 % of the volume of the In the present invention , porogen particles generally refer 
composition ( or any sub - range within these ranges ) . 25 to biodegradable particles of the micron scale that are 
In many embodiments , biodegradable reinforcing par - dispersed in the polymer matrix . In addition , the porogen 
ticles may be anisotropic particles ( i . e . particles that have particles of the present invention may be associated with one 
one of their dimensions ( e . g . , length or thickness ) substan or more active agents . Upon degradation , the porogen par 
tially different from the other two , which may define a ticles of the present invention may leave interconnected 
cross - section of the particle ) . 30 porosity throughout the matrix while simultaneously releas 
An aspect ratio of the biodegradable reinforcing particle ing active agents ( e . g . , cells ) . In addition , the porogen 
may be defined as a ratio between the length or thickness and particles of the present invention may contain within them 
its mean lateral dimension ( i . e . , mean dimension of its additional particles , such as biodegradable porous particles 
cross - section ) . Such a mean lateral dimension may be a ( e . g . , silicon porous particles ) . 
diameter of a circular cross - section , a side - length for a 35 In various embodiments , the porogen particles of the 
square cross - section , or a square root of a product of two present invention ( including any particles within the poro 
lateral dimensions for structures that have a cross - section gen particles ) may be hydrogel porogen particles ( e . g . , 
characterized by two dimensions ( such as a rectangular alginates , fibrins , and gelatins ) , natural or synthetic biode 
cross - section or an elliptical cross - section ) . For the aniso - gradable particles ( e . g . , particles derived from or coated with 
tropic particle , the aspect ratio is substantially different than 40 poly ( lactic - co - glycolic acid ) ( PLGA ) ) , biodegradable 
porous particles ( e . g . , silicon porous particles ) , and biocom 
In many embodiments , the biodegradable reinforcing patible vesicles ( e . g . , liposomes and / or micelles ) . 
particle may be an elongated , rod - like particle . In some In various embodiments , a surface of a porogen particle 
embodiments , the biodegradable reinforcing particles have ( or a surface of a particle within the porogen particle ) is 
an aspect ratio of at least 2 , at least 4 , at least 10 , at least 20 , 45 modified with a biodegradable polymer . In some embodi 
at least 50 , at least 100 , at least 200 , at least 500 , or at least ments , the biodegradable polymer is agarose . In further 
1000 . Such elongated particles may be prepared using the embodiments , the biodegradable polymer is PLGA . In more 
methods disclosed in the Examples below . Such elongated specific embodiments , porogen particles contain biodegrad 
particles may be also be prepared using the techniques able porous particles within them ( e . g . , silicon porous par 
disclosed in U . S . patent application Ser . No . 13 / 044 , 250 and 50 ticles ) that are coated with a biodegradable polymer ( e . g . , 
PCT Application No . PCT / US11 / 27746 . PLGA and / or agarose ) . 
In various embodiments , biodegradable reinforcing par - Without being bound by theory , Applicants envision that 
ticles of the present invention may have a cross - section porogen particles of the present invention can help facilitate 
having the greater of lateral dimension ( s ) of no more than 10 or control various properties of the compositions of the 
microns , no more than 5 microns , no more than 2 microns , 55 present invention . For instance , in some embodiments , poro 
no more than 1 micron , no more than 500 nm , no more than gen particles may help facilitate or control the bio - distribu 
200 nm , no more than 100 nm , or no more than 50 nm . In tion of active agents to various parts of an organism ( e . g . , 
many embodiments , the smaller of the lateral dimension ( s ) cells , tissues , organs , etc . ) . 
of the biodegradable reinforcing particles ' cross - section is In further embodiments , porogen particles can help facili 
no more than 5 microns , no more than 2 microns , no more 60 tate or control the intracellular delivery of active agents to 
than 1 micron , no more than 500 nm , no more than 200 nm , various organelles ( e . g . , lysosomes , cytoplasm and nuclei ) . 
no more than 100 nm , or no more than 50 nm . In many For instance , in some embodiments , porogen particles can 
embodiments , the smaller of the lateral dimension ( s ) of the prevent or guide particles to lysosomes , cytoplasms , nuclei 
cross - section of the biodegradable reinforcing particles may or other cellular organelles . 
be no more than 5 microns , no more than 2 microns , no more 65 In addition , porogen particles may help facilitate the 
than 1 micron , no more than 500 nm , no more than 200 nm , internalization of the particle by various cells and organelles . 
no more 100 nm , or no more than 50 nm . For instance , in some embodiments , an agarose coating on 
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a biodegradable porous particle within a porogen particle In some embodiments , the hydrogel - based porogen par 
may help enhance active agent delivery to the nuclei of cells . ticles may contain a metal ion , which may be replaced or 
In additional embodiments , porogen particles of the pres dissociated from the complex to facilitate a degradation of 
ent invention may help facilitate , preserve or control the the porogen particle . Such a replacement may be initiated by 
stability of active agents . For instance , in cases where the 5 a degradation initiator , such as a chelation agent . The 
active agent is a protein , porogen particles of the present degradation initiator may be contained in one or more 
invention may help prolong protein stability by preserving microparticles or nanoparticles , which may be dispersed in 
the polymer matrix or contained inside the porogen particle . protein structure over time and protecting the protein from In some cases , the microparticle or nanoparticle containing enzymatic digestion . 
In some embodiments , the porosity and pore interconnec 10 the degradation initiator may be a reinforcement micropar ticle or nanoparticle , as discussed above . In more specific tivity within the compositions of the present invention may embodiments where the porogen is an alginate , the replace be created in vivo using porogen particles . In some embodi able metal ion in the hydrogel may be calcium , and the ments , the porogen particles may have the ability to encap degradation initiator may be a calcium chelating compound , 
sulate cells , such as stem cells , an / or active agents , such as 15 such as a phosphate ( e . g . . sodium phosphate ) , a citrate ( e . g . 
therapeutic and / or imaging agents . In some embodiments , sodium citrate ) or a lactate ( e . g . , sodium lactate ) . 
the porogen particles may contain or encapsulate one or In addition to their porogenic role , the porogen particles 
more proteins . For example , in certain embodiments , of the present invention may also serve as a delivery vehicle 
plateletrich plasma ( PRP ) , which is a blood derived liquid for delivering one or more active agents , such as an imaging 
that may provide proper ECM - like protein for cellular 20 agent and / or a therapeutic agent ( as discussed above ) . In 
attachment and release one or more native factors from such a case , one or more active agents may be contained 
platelets to recruit and proliferate cells , may be integrated or inside the porogen particle . In some embodiments , active 
incorporated within the porogen particles . Such incorpora - agents may be contained in particles within porogen par 
tion may contribute to obtaining a desired size of the ticles . 
porogen particles , which may be from 100 microns to 700 25 Non - limiting examples of active agents which may be 
microns , from 150 microns to 600 microns , or from 200 contained inside the porogen particle may include antibiot 
microns to 500 microns . Such incorporation may also pro - ics , proteins ( e . g . , growth factors ) , platelet rich plasma , cells 
vide a sustained release of growth factors from the porogen ( e . g . , stem cells ) , degradation inducers of porogen particles 
particles . ( e . g . , lactic acid ) , anti - inflammatory agents , and nucleic 
In various embodiments , the porogen particles of the 30 acids ( e . g . , DNA and / or siRNA ) . In further embodiments , 
present invention may degrade in a body of a patient with a the porogen particle associated with the active agent is a 
rate faster than a biodegradation rate of the biodegradable biodegradable porous particle . In more specific embodi 
polymer of the matrix , thereby forming a porous network in ments , the porogen particles comprise alginate , and the 
the matrix . In some embodiments , such a porous network active agent is a degradation inducer that comprises sodium 
may be necessary for formation of new vasculature at a bone 35 citrate . In more specific embodiments , the alginate - based 
defect site . In some embodiments , the biodegradation rate of particle containing sodium citrate is within another porogen 
the porogen particles may be no more than 3 months , no particle . 
more than 2 months , no more than 1 month , no more than 2 In further embodiments , the porogen particles may con 
weeks , no more than 10 days , no more than 7 days , no more tain one or more growth factors , such as PDGFaß , 
than 6 days , no more than 5 days , no more than 4 days , no 40 PDGFad , PDGFBB , TGF1 , TGF2 , vascular endothelial 
more than 3 days , no more than 2 days , or no more than 1 growth factor ( VEGF ) and epithelial growth factor ( EGF ) . In 
day . some embodiments , the porogen particle may contain one or 
In various embodiments , the porogen particles of the more proteins , such as fibrin , fibronectin and vitronectin . 
present invention may have a characteristic size , such as a Such proteins may act as cell adhesion molecules for osteo 
diameter that may range from 100 microns to 700 microns , 45 conduction and as matrix for bone , connective tissue and / or 
from 150 microns to 600 microns , or from 200 microns to epithelial growth . 
500 microns . In further embodiments , the porogen particles In some embodiments , the porogen particles may contain 
of the present invention may constitute from 20 % to 95 % , platelet - rich plasma ( PRP ) , which may be released from the 
from 25 % to 90 % , from 30 % to 80 % , or from 35 % to 75 % porogen matrix . PRP may contain PDGFaß , PDGFaa , 
of the volume of the composition . 50 PDGFBB , TGF1 , TGF2 , VEGF , EGF , fibrin , fibronectin 
In more specific embodiments , the porogen particles of and / or vitronectin . 
the present invention ( or any particles within them ) may be In some embodiments , the porogen particles may contain 
hydrogel porogen particles ( i . e . particles comprising a natu - smaller size microparticles or nanoparticles , which may also 
ral or synthetic hydrogel ) . Examples of natural hydrogels contain one or more active agents , such as those mentioned 
include hydrogels based on natural biodegradable polymers , 55 above . Such microparticles or nanoparticles may be porous 
such as gelatin or collagen . Examples of synthetic hydrogels or mesoporous microparticles or nanoparticles . Such porous 
include hydrogels based on synthetic biodegradable poly - or mesoporous particles may be silicon or silica porous 
mers , such as oligo ( poly ( ethylene glycol ) fumarate ( OPF ) . particles such as those disclosed in one of the following 
In some embodiments , the hydrogel material in the poro - documents : ( 1 ) PCT publication no . WO 2007 / 120248 ( pub 
gen particle may comprise a polysaccharide polymer . In 60 lished on Oct . 25 , 2007 ) ; ( 2 ) PCT publication no . WO 
some embodiments , the hydrogel material may be an anionic 2008 / 041970 ( published on Apr . 10 , 2008 ) ; ( 3 ) PCT publi 
polysaccharide , such as alginate . Various suitable porogen cation no . WO 2008 / 021908 ( published on Feb . 21 , 2008 ) ; 
particles ( including alginate ) are disclosed in WO2005 / ( 4 ) U . S . Patent Application Publication No . 2008 / 0102030 
020849 , US2008 / 0206308 , U . S . Pat . No . 6 , 656 , 508 , US ( published on May 1 , 2008 ) ; ( 5 ) U . S . Patent Application 
2002 / 0001619 , US 2002 / 0168406 , WO2008 / 006658 , 65 Publication No . 2003 / 0114366 ( published on Jun . 19 , 2003 ) ; 
WO2008 / 073856 , EP1664168 , US2007 / 0178159 , and ( 6 ) U . S . Patent Application Publication no . 2008 / 0206344 
WO2007 / 089997 . ( published on Aug . 28 , 2008 ) ; ( 7 ) U . S . Patent Application 
US 10 , 058 , 633 B2 
15 
Publication no . 2008 / 0280140 ( published on Nov . 13 , 2008 ) ; spheroid , a disc or a cylinder . In some embodiments , the 
( 8 ) PCT Patent Application PCT / US2008 / 014001 , filed on porous particle may be a truncated oblate spheroidal particle . 
Dec . 23 , 2008 ; ( 9 ) U . S . Pat . No . 6 , 107 , 102 ( issued on Aug . The microparticles or nanoparticles within the porogen 
22 , 2000 ) ; ( 10 ) U . S . Patent Application Publication No . particles of the present invention may also comprise a 
2008 / 0311182 ( published on Dec . 18 , 2008 ) ; ( 11 ) PCT 5 porous oxide material or a porous etched material . Examples 
Patent Application No . PCT / US2009 / 000239 ( filed on Jan . of porous oxide materials include , but are not limited to , 
15 , 2009 ) ; ( 12 ) PCT Patent Application No . PCT / US11 / porous silicon oxide , porous aluminum oxide , porous tita 
27746 ( filed on Mar . 9 , 2011 ) ; ( 13 ) U . S . Patent Application nium oxide and porous iron oxide . The term “ porous etched 
Publication No . 2010 / 0029785 ( published on Feb . 4 , 2010 ) ; materials ” refers to a material , in which pores are introduced 
( 14 ) Tasciotti E . et al , 2008 Nature Nanotechnology 3 , 10 via a wet etching technique , such as electrochemical etching 
151 - 157 ; ( 15 ) PCT Application No . PCT / US11 / 28861 ( filed or electroless etching . Examples of porous etched materials 
on Mar . 17 , 2011 ) ; ( 16 ) PCT Application No . PCT / US11 / include porous semiconductors materials , such as porous 
28890 ( filed on Mar . 17 , 2010 ) ; ( 17 ) U . S . Provisional Patent silicon , porous germanium , porous GaAs , porous InP , 
Application No . 61 / 282 , 798 ( filed on Apr . 1 , 2010 ) ; and ( 18 ) porous SiC , porous Si Gel - x ; porous GaP and porous GaN . 
U . S . Provisional Patent Application No . 61 / 322 , 766 ( filed 15 Methods of making porous etched particles are disclosed , 
on Apr . 9 , 2010 ) . Each of the above documents are incor - for example , US Patent Application Publication no . 2008 / 
porated herein by reference in their entirety . 0280140 . 
In some embodiments , the above - described micropar - In some embodiments , the porogen particles of the pres 
ticles or nanoparticles within the porogen particles may ent invention may be a nanoporous particle . In some 
allow for a release of one or more active agents within the 20 embodiments , an average pore size of the nanoporous par 
particles in a controlled and sustained fashion . In various ticle may be from about 1 nm to about 1 micron , from about 
embodiments , such controlled and sustained release may 1 nm to about 800 nm , from about 1 nm to about 500 nm , 
allow for optimizing a healing or regeneration process . For from about 1 nm to about 300 nm , from about 1 nm to about 
instance in a case of treating a bone defect ( such as a bone 200 nm , or from about 2 nm to about 100 nm . In some 
fracture ) the controlled and sustained release of active 25 embodiments , the average pore size of the nanoporous 
agents from the microparticles or nanoparticles may allow particle can be no more than 1 micron , no more than 800 nm , 
for optimizing the bone healing and / or regeneration process . no more than 500 nm , no more than 300 nm , no more than 
The active agents which may be contained inside the 200 nm , no more than 100 nm , no more than 80 nm , or no 
microparticles or nanoparticles of the above - described poro - more than 50 nm . 
gen particles may include antibiotics , anti - inflammatory 30 In some embodiments , the average pore size of the 
agents , proteins ( such as growth factor ) , and nucleic acids nanoporous particle can be from about 5 nm to about 100 
( such as DNA and siRNA ) . In some embodiments , the nm , from about 10 nm to about 60 nm , from about 20 nm to 
growth factors may include one or more of PDGFaß , about 40 nm , or from about 30 nm to about 30 nm . In some 
PDGFaa , PDGFBB , TGF1 , TGF2 , vascular endothelial embodiments , the average pore size of the porous particle 
growth factor ( VEGF ) and / or epithelial growth factor 35 can be from about 1 nm to about 10 nm , from about 3 nm 
( EGF ) . In some embodiments , the microparticles or nano - to about 10 nm , or from about 3 nm to about 7 nm . 
particles may contain one or more proteins , such as fibrin , In general , pores sizes may be determined using a number 
fibronectin and vitronectin . In some embodiments , the micro of techniques , including N , adsorption / desorption and 
or nanoparticle may contain platelet - rich plasma ( PRP ) . PRP microscopy , such as scanning electron microscopy . In some 
may contain PDGFaß , PDGFaa , PDGFBB , TGF1 , TGF2 , 40 embodiments , pores of the nanoporous particle may be 
VEGF , EGF , fibrin , fibronectin and / or vitronectin . linear pores . Yet , in some embodiments , pores of the nano 
The above - described microparticles or nanoparticles porous particle may be sponge like pores . 
within the porogen particles may also have a variety of A person of ordinary skill in the art can also envision that 
shapes and sizes . In some embodiments , the maximum various methods may be used to load active agents into the 
characteristic size of the particles may be less than about 100 45 porous particles . Methods of loading active agents into 
microns , less than about 50 microns , less than about 20 porous particles are disclosed , for example , in U . S . Pat . No . 
microns , less than about 10 microns , less than about 5 6 , 107 , 102 and US Patent Application Publication No . 2008 / 
microns , less than about 4 microns , less than about 3 0311182 . 
microns , less than about 2 microns , or less than about 1 In some embodiments , the porous particles within the 
micron . Yet , in some embodiments , the maximum charac - 50 porogen particles of the present invention are porous silicon 
teristic size of the particles may be from 100 nm to 3 particles . In general , porous silicon may be bioinert , bioac 
microns , from 200 nm to 3 microns , from 500 nm to 3 tive or biodegradable , depending on its porosity and pore 
microns , or from 700 nm to 2 microns . size . Also , a rate or speed of biodegradation of porous silicon 
Yet , in some embodiments , the maximum characteristic size may depend on its porosity and pore size . See e . g , Canham , 
of the particle may be greater than about 2 microns , greater 55 Biomedical Applications of Silicon , in Canham L T , editor . 
than about 5 microns , or greater than about 10 microns . Properties of porous silicon . EMIS datareview series No . 18 . 
A person of ordinary skill in the art will also recognize London : INSPEC . p . 371 - 376 . The biodegradation rate of 
that the shape of the microparticles or nanoparticles within porous silicon particles may also depend on surface modi 
the porogen particles is not particularly limited . In some fication . Porous silicon particles and methods of their fab 
embodiments , the microparticles or nanoparticles may be a 60 rication are disclosed , for example , in Cohen M . H . et al 
spherical particle . Yet , in some embodiments , the particles Biomedical Microdevices 5 : 3 , 253 - 259 , 2003 ; US Patent 
may be a non - spherical particle . In some embodiments , the Application Publication No . 2003 / 0114366 ; U . S . Pat . Nos . 
microparticles or nanoparticle can have a symmetrical 6 , 107 , 102 and 6 , 355 , 270 ; US Patent Application Publication 
shape . Yet , in some embodiments , the microparticles or No . 2008 / 0280140 ; PCT Publication No . WO 2008 / 021908 ; 
nanoparticle may have an asymmetrical shape . 65 Foraker , A . B . et al . Pharma . Res . 20 ( 1 ) , 110 - 116 ( 2003 ) ; 
In some embodiments , the microparticles or nanoparticles and Salonen , J . et al . Jour . Contr . Rel . 108 , 362 - 374 ( 2005 ) . 
may have a selected non - spherical shape , such as an oblate Porous silicon oxide particles and methods of their fabrica 
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tion are disclosed , for example , in Paik J . A . et al . J . Mater . body of the subject after the injecting . In further embodi 
Res . , Vol 17 , August 2002 , p . 2121 . ments , the scaffold that is applied also comprises at least one 
In some embodiments , the porous particle may be a porogen particle , as described above . In further embodi 
particle produced utilizing a top - down microfabrication or ments , the applied scaffold also comprises one or more 
nanofabrication technique , such as photolithography , elec - 5 active agents , as also described . 
tron beam lithography , X - ray lithography , deep UV lithog - Bone defects that can be treated with the scaffolds of the 
raphy , nanoimprint lithography or dip pen nanolithography . present invention include , without limitation , bone fractures , 
Such fabrication methods may allow for a scaled up pro maxillofacial defects , craniofacial defects , spine defects duction of particles that are uniform or substantially iden ( e . g . , defects and / or injuries in intervertebral bodies ) , long tical in dimensions . 10 bone defects ( e . g . , weight bearing and non - weight bearing Active Agents defects ) , and combinations thereof . In various embodiments , As set forth above , the individual components of the the aforementioned defects to be treated may be critical size compositions of the present invention may be associated 
defects and / or non - critical size defects . with one or more active agents . In various embodiments , the 
active agent may be associated with the biodegradable 15 ble 15 Methods of Making Biodegradable Compositions 
polymer matrix , the biodegradable reinforcing particle , and / Additional aspects of the present invention pertain to 
or the porogen particle . methods of making the above - mentioned biodegradable 
In some embodiments , the active agent comprises antibi - compositions . Such methods generally comprise dispersing 
otics , proteins , platelet rich plasma , cells ( e . g . , stem cells ) , in a biodegradable polymer matrix at least one biodegrad 
degradation inducers of porogen particles ( e . g . , lactic acid 20 able reinforcing particle , as previously described . Such 
and / or sodium citrate ) , anti - inflammatory agents , cell viabil - methods may also involve the dispersion of porogen par 
ity enhancing agents ( e . g . , glucose ) , and / or imaging agents ticles and / or active agents into the biodegradable polymer 
( e . g . , barium sulfate , ) . More specific examples of active matrix . Additional details about such methods are described 
agents were described above . Additional active agents that in the Examples below . 
may be suitable for use with the compositions of the present 25 Advantages and Applications 
invention are disclosed in PCT Application Nos . PCT / US11 / The methods and compositions of the present invention 
28861 and PCT / US11 / 28890 , both filed on Mar . 17 , 2010 . provide numerous advantages . One of the advantages of the Use of Biodegradable Compositions as Scaffolds compositions of the present invention may lie in the com In various embodiments , the compositions of the present positions ' mulitifunctionality , as the composition may have 
invention may be utilized as scaffolds . In a specific example , 30 one or more of the following properties : optimal mechanical the scaffolds of the present invention may be used for characteristic ; injectability for irregular defects ; and mul treating bone defects , such as bone fractures , maxillofacial tiple ( i . e . two or more ) stages of bioactive release to enhance defects , and craniofacial defects . Scaffolds of the present 
invention may also be utilized for tissue engineering , tissue the bone healing process . The scaffold and compositions of 
regeneration , and wound healing . In additional embodi - 35 di 35 the present invention may also be capable of providing one 
ments , the scaffolds and compositions of the present inven or more of the following advantages : i ) cross - linking in situ , 
tion may be used for treating or preventing a microbial ii ) conforming to a bone geometry , iii ) providing immediate 
infection , such as a bacterial infection at a site of a bone mechanical stability , iv ) providing a continuous delivery of 
defect . one or more active agents , which may be , for example , 
In more specific embodiments , the scaffolds of the present 40 antibiotics and growth factors ; v ) promoting accelerated 
invention may be used in treating soft tissue injuries and tissue regeneration and vi ) degrading into benign by - prod 
facilitating ligament / tendon repair . Likewise , the scaffolds ucts that may be resorbed and excreted by the body . 
of the present invention may find various applications in An additional advantage of the compositions of the pres 
tooth regeneration , neural repair ( e . g . , facilitation of spinal e nt invention may be the ability to vary biodegradation 
cord regeneration ) , and intervertebral disc replacement . The 45 and / or release rates of various components . For instance , the 
scaffolds of the present invention may also be used to treat present compositions may allow for the biodegradation 
cartilage defects . Likewise , the scaffolds of the present and / or release process to be adjusted to match the kinetics of 
invention may be utilized as vascular grafts . The scaffolds of the bone regeneration process and thus , progressively trans 
the present invention may also be used to make or engineer fer the loads from the scaffold to the new tissue . The 
artificial tissues or organs , such as an engineered pancreas 50 development of bone architecture may be naturally driven 
for type 1 diabetic patients . Additional applications for the by the mechanical forces applied . As a result , osteoclasts 
scaffolds of the present invention can also be envisioned by may begin resorbing bone that is not subjected to the 
persons of ordinary skill in the art . appropriate load and only remodel the newly formed bone in 
Application of Scaffolds for Treatment of Bone Defects areas of high stress . 
As set forth previously , a specific embodiment of the 55 The tunability of both the release of active agents , such as 
present invention pertains to methods of treating a bone therapeutic agents and / or imaging agents , and degradation 
defect in a subject by applying to an area of the bone defect rates of each individual component in the scaffold may also 
in the subject a scaffold of the present invention . For provide the ability to mimic and accelerate one or more 
instance , in some embodiments , the bone defect treatment natural regeneration processes . For instance , the scaffolds 
methods of the present invention include : ( 1 ) applying to an 60 and compositions of the present invention may be designed 
area of the bone defect in the subject a scaffold that to provide immediate stability to a minor or substantial bone 
comprises : ( a ) a biodegradable polymer matrix , and ( b ) at defect . The present compositions and scaffolds of the present 
least one biodegradable reinforcing particle dispersed in the invention may also simultaneously initiate and / or accelerate 
matrix , as previously described . In further embodiments , the the natural healing cascade . 
applying step comprises injecting the subject with a com - 65 Additional aspects of the present invention will now be 
position of the present invention . In additional embodi - described with reference to specific and non - limiting 
ments , the scaffold is formed from the composition in the Examples . 
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EXAMPLES contrary , solid alginate beads may degrade in a longer time 
and may therefore provide a sustained release over 1 week 
Example 1 . Scaffold Components or 2 weeks or 3 weeks or 4 weeks . To induce degradation of 
alginate porogen particles , the reinforcing microparticles or 
FIGS . 1A - 1F shows alginate hydrogel microspheres 5 nanoparticles may be loaded with the calcium chelation 
encapsulating cells and bioactive molecules . Inside of the agent , sodium citrate , and encapsulated within the alginate 
above porogen ( ~ 200 - 500 microns ) is PRP as well as porogen itself . As the sodium citrate is slowly released from 
mesenchymal stem cells ( FIG . 1A - 1B optical image , FIG . the reinforcing microparticles or nanoparticles , the calcium 
1C confocal image green - cells , FIG . 1D - 1F SEM image ) . ions that gel the alginate may be replaced with citrate ions Also within the porogen may be microparticles or nanopar - 10 cau causing the gel to disassemble and “ dissolve . ” The rate at ticles , which may be coated with a polymer , such as agarose which this degradation may occur may be controlled . or PLGA , that may also contain one or more active agents Secondly , upon the porogen particle degradation , the loaded within the nanopores ( FIG . 2 ) . microparticles or nanoparticles that were contained inside The porogen may be dispersed within a viscous polymer 
matrix , such as a PPF matrix , that may contain silica 15 the porogen particles may be released with the PRP in stage 
nanorods as mechanical reinforcement ( FIGS . 3A - 3D ) . In one . In case , when these micro or nanoparticles are mes 
some embodiments , the composition with some or all men oporous silicon microparticles or nanoparticles , they may be 
tioned components may be loaded into a syringe and coated with a bulk degrading polymer , such as PLGA or 
injected into the bone defect where it may crosslink in the agarose , which may provide a further extended sustained 
shape of the bone defect geometry ( FIG . 4 ) . Yet , in some 20 release . 
embodiments , the composition may be used for forming a In some embodiments , the mesoporous silicon micropar 
scaffold ex situ . After cross - linking , the scaffold composite ticles or nanoparticles may be biodegradable porous silicon 
may conform to the defect geometry as seen below in FIG . with well controlled shapes , sizes and pores . The size of the 
5 using a cylindrical mold . pores may confine the space for the entrapment of an active 
25 agent of choice while the porous silicon surface chemistry 
Example 2 . Release of Active Agents from may affect the stability and duration of its interaction with 
Scaffolds for Treatment the active agent . 
The ability to load active agents within the porous matrix 
The multifaceted nature of the injectable matrix may of the particle at room temperature may enable the use as the 
provide ideal means of staggering the delivery of the above - 30 act active agent sensitive compounds susceptible to temperature mentioned active agents that may enhance stem cell activity dependent degradation or inactivation . Polymer coating of at rates contingent upon the corresponding stage of fracture the mesoporous micro or nanoparticles , such as mesoporous healing . For example , PRP may provide a cocktail of all silicon micro or nanoparticles , may allow avoiding the burst necessary growth factors with the additional advantage of presenting them in optimal ratios for cell growth . PRP may 35 release of the active agent , such as an antibiotic from the 
therefore be a supplier of bioactive molecules throughout the pores and to achieve its sustained release over the course of 
entire scaffold and may be contained in one or more com a week . Pore size and coating strategy may be used in 
ponents of the composition and a scaffold formed therefrom , parallel to provide sustainable release of active agents to 
such as the porogen particles , the reinforcing microparticles enhance process of healing cascade and to prevent the 
or nanoparticles , the microparticles or nanoparticles with the 40 establishment of possible infections in a bone defect site , 
porogen particles and the polymer matrix . In some embodi - such as fracture site . 
ments , PRP may be contained in more than one of the above Thirdly , for the final and longest delay of release , the 
mentioned components of the composition or the scaffold . In reinforcing particles embedded within the polymer matrix 
some embodiments , PRP may be contained in each of the may release PRP as the surrounding polymer matrix 
above mentioned components of the composition or the 45 degrades exposing the pores of the reinforcing particles to 
scaffold . the defect site . Due to the various rates of degradation of 
In some embodiments , one or more antibiotics may be each above mentioned components , the needs of each phase 
incorporated into one or more components of the composi - of the healing cascade may be met . 
tion and a scaffold formed therefrom , such as the porogen The composition may be a composite material having the 
particles , the reinforcing microparticles or nanoparticles , the 50 texture of a paste enabling it to conform to different shapes 
microparticles or nanoparticles with the porogen particles according to the specific application and including the 
and the polymer matrix . In some embodiments , one or more reconnection of separated bones and the replacement of 
antibiotics may be contained in more than one the above missing bone . In some embodiments , the composition may 
mentioned components of the composition or the scaffold . In be used for treating bone defects , such as fracture or an 
some embodiments , one or more antibiotics may be con - 55 injury for a bone in a body of an animal , which can be a 
tained in each of the above mentioned components of the warm bloodied animal , such a mammal , which may be a 
composition or the scaffold . Overall , the present system may human . For example , the composition may be used for 
provide antibiotics during the entirety of the healing process treating a bone fracture or an injury in a human body bone , 
of a bone defect , such as bone fracture . such as a spine , a skull or a facial bone . 
The operation of the scaffold in some embodiments may 60 FIG . 6A - 6F schematically depicts the use of the compo 
be illustrated as follows : The immediate delivery of growth sition for vertebral body compression fractures . PPF refers 
factors may be supplied through the PRP dispersed within to the polymer matrix , which may be poly ( propylene fumar 
the porogen particles . Upon degradation of the porogen ate ) ; MSN refers to reinforcing micro or nanoparticles , 
particles , the PRP may be released into the defect site . A which may mesoporous silica nanorods ; SE refers to micro 
faster degradation ( and a faster release ) may be achieved by 65 or nanoparticles inside the porogen beads , such micro or 
using as porogen particles alginate capsules with a thin layer nanoparticles may be mesoporous silicon micro or nanopar 
of alginate surrounding the encapsulated content . On the ticles . 
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Example 3 . Synthesis , Characterization and Use of with 1 % Tween 80 to remove residual oil . Due to the size 
Alginate Porogens distribution , a method of sieving out unwanted sizes was 
developed . Briefly , a 500 micron ASTM sieve was used to 
The following example provides steps for incorporation remove all beads larger than 500 microns , and a 212 micron 
of cells and platelet - rich plasma ( PRP ) and bioactive mol - 5 sieve was used to remove all beads smaller than 212 
ecules into an alginate microsphere matrix during a fabri - microns . 
cation process . Characterization of Alginate Porogens 
Protocol for Synthesis of Alginate Porogen Microparticles FIG . 1A provides optical images of alginate porogens 
with the Incorporation of Cells and Platelet - Rich Plasma with PRP ( top left ) , and alginate porogens with mesenchy 
As depicted in FIG . 7C - 7E , Calcium alginate beads were 10 mal stem cells ( FIG . 1B , top center ) . FIG . 1C also shows 
synthesized by emulsion in mineral oil with low surfactant confocal microscopy images of alginate porogens with mes 
conditions and acetic acid as a catalyst . In order to optimize enchymal stem cells labeled with green fluorescence ( CSFB ) 
the process and accomplish beads with sizes ranging from ( top right ) . In addition , FIGS . 1D - 1F shows SEM images of 
300 - 500 um , the concentration ratio of sodium alginate and alginate porogens ( bottom ) . 
platelet - rich plasma , the amount and type of surfactant , the 15 Alginate porogens were fabricated using the above - men 
stir rate and size of beaker and stir bar used for creating an tioned protocol and were characterized by optical micros 
optimal volume were all varied within the same protocol . copy ( FIG . 1A - 1B ) ( Nikon Eclipse TS 100 ) , confocal 
Select runs of this process are provided in Table 1 below . microscopy ( FIG . 1C ) ( Leica MD 6000 ) , and scanning 
TABLE 1 
Runs 1 - 6 : Variables manipulated , values employed , bead size range obtained . 
Percent 
Alginate 
Solution 
2 
Starting pH of 
Alginate Solution 
Surfactant 
Concentration 
( Span80 ) Stir Speed 
Bead Size Range 
( average ) Run 
1 
Notes 
2 7 .55 7 . 55 2 % 2 on VWR 80 - 100 um Did not sonicate CaCO3 prior to 
addition to 
alginate . Added 
CaCl2 to alginate 
mineral oil 
mixture 
Added Alginate 
mineral oil 
mixture to CaCl2 
2 2 7 . 55 7 . 55 4 % 2 on VWR 80 - 200 um 
5 0 uus 7 . 65 7 . 61 4 % 4 % 5 - 6 on Cimarec 80 - 250 um 4 on Cimarec 80 - 300 um Larger beads but 
increased 
clumping ( as seen 
in 4b ) 
0 u 7 . 58 3 % 7 .58 
7 . 56 
3 % 
3 % 
5 - 6 on Cimarec Poor shape . , 
difficult to 
characterize 
4 on Cimarec 80 - 300 um 6 4 7 . 56 3 % Some clumping , a 
few beads in 300 um 
range 
The addition of PRP into the alginate matrix was found to 45 electron microscopy ( SEM ) ( FEI Quanta 400 ESEM FEG ) 
be essential to create a desired viscosity for bead creation ( FIGS . 1D - 1F ) . The samples were sputtered with 20 nm gold 
within the aimed 200 - 500 microns . The difference in size is by a Plasma Sciences CrC - 150 Sputtering System ( Torr 
illustrated in FIGS . 7A - 7B and 7F . International , Inc ) prior to SEM analysis . 
The protocol for the incorporation of live cells into the FIGS . 1B - 1C ( top center and top right ) also includes 
microparticles is as follows : 5 grams of sodium alginate was images of mesenchymal stem cells stained with a fluorescent 
slowly dissolved in 75 mM NaC1 / 12 . 5 mM HEPES in dye . Calcium alginate beads were synthesized by the emul 
PRP : D1 water ( 1 : 1 ) ( 5 % w / v ) . The pH of the solution was sion process described above with the incorporation of cells 
adjusted to a value of ~ 7 . 5 . Sonicated aqueous CaCO3 into the aqueous alginate phase . The stem cells were stained 
mixture with 500 mM Ca2 + equivalent was then added to 55 with the green fluorescence dye Carboxyfluorescein diac 
the alginate solution . Mesenchymal stem cells were then etate , succinimidyl ester ( CSFE ) using a 25 um staining 
added to the alginate solution suspended in PRP . The alg - solution . After 12 hours of incubation post - staining , the cells 
inate - cell - CaCO3 mixture was then added to a solution of were trypsinized and re - suspended in the 5 % alginate / PRP 
mineral oil with 2 Span80 by volume and stirred with a solution at 2x10 cells per ml . The emulsion was then 
magnetic stir bar for 15 minutes . With continued stirring , a 60 performed as described above , thereby creating alginate and 
mixture of mineral oil and glacial acetic acid was slowly PRP beads encapsulating live cells . Beads with cells were 
added and allowed to mix for 10 additional minutes to then incubated in DMEM complete media ( 10 % FBS , 1 % 
initiate the release of calcium from the carbonate and the antibiotic ) at 37 degrees Celsius prior to imaging . 
subsequent gelation of the calcium alginate beads . Beads Enhancing the Mechanical Properties of a Porous Poly 
were then separated from the oil dispersion by partitioning 65 mer Matrix Through Incorporation of Alginate Porogens 
the mixture above into an aqueous CaCl , solution . The beads PPF and alginate scaffolds were created using Teflon 
were then collected by pipette and washed on a vacuum filter molds with dimensions 6 mm dx12 mm h . Briefly , the PPF 
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monomer was diluted with N - vinyl - 2 - pyrrolidone ( NVP ) FIG . 10B . Similarly , the stimulatory effect of RANTES 
using a 1 : 4 ratio prior to dispersion . A mixture of 40 % release from the complex is illustrated in FIG . 10C . Fur 
alginate porogens by weight within PPF was mechanical thermore , the induction of angiogenesis was been confirmed 
stirred . 20 mg of benzoyl peroxide ( BP ) was then added to in a Lewis Rat subcutaneous implantation of the PRP / 
initiate the cross - linking of PPF along with N , N - Dimethyl - 5 alginate porogens ( FIG . 10D ) . 
p - toluidine ( DMT ) to accelerate the reaction . The mixture Cryopreservation of Biological Components 
was then poured into the Teflon mold and placed at 60 As shown in the cell viability assays of FIG . 10E , porogen degrees Celsius overnight to fully cross - link . particles also provide cell viability protection during the The compressive mechanical properties of the alginate injecting and cross - linking process of the polymer scaffold . incorporating constructs were measured according to 10 Furthermore , as demonstrated in FIG . 10F , The degradation ISO5833 standards . 6 mmx12 mm cylindrical scaffolds of the porogen can be artificially controlled through the ( n = 5 ) incorporating 40 % alginate microspheres by weight controlled delivery of calcium chelation agents that cause were compressed along their long axis using a mechanical 
testing machine with a 10 kN load cell ( MTS ) . As a dissolution of the porogens . 
comparison , 80 % salt PPF scaffolds of equivalent size were 15 Example 4 . Synthesis and Characterization of Silica created and the salt leached out to create a porous structure . 
The 80 % salt porous scaffolds were then tested using the Nanorods 
same methods described above . The young ' s modulus and 
stress at offset yield were recorded and are illustrated in The following experiments pertained to porous silica 
FIGS . 8A - 8B , respectively . 20 nanorod fabrication with desired aspect ratios for mechani 
Results from MTS Testing Showing Mechanical Rein cal reinforcement . In the adjustments of reagents such as 
forcement Due to Presence of Alginate Microparticle Poro - ammonia , CTAB , TEOS and 3 - ( trimethoxysilyl ) propyl 
gens methacrylate silane , the aspect ratio of the silica may be 
As summarized in FIGS . 8A - 8B , the alginate porogens increased to the desired size for nano reinforcement . In 
provide an 8 - fold increase in mechanical strength compared 25 addition , mesoporous silica nanorods may contain one or 
to pre - fabricated PPF porous scaffolds by temporarily filling more active agents ( including but not limited to , contrast 
the voids until they undergo biodegradation . Furthermore , agents , metallic ions , fluorescent dyes , and cations ) , which 
the elastic modulus of the porogen composite provides a may be incorporated into porous silica nanorod matrices 
significantly closer match to that of trabecular bone within during the fabrication process . The following protocols also 
the vertebral body ( 165 - 291 MPa ) ' than the current PMMA 30 describe surface modification methods to covalently bond 
standard ( 48 - 76 MPa ) ? . the porous silica nanorod to the backbone ( or side chains ) of 
The addition of calcium alginate porogens into the ( PPF ) polymer matrices to be reinforced . 
based matrix renders the temperature increase , from the Protocol for Synthesis of Silica Nanoparticles with Incor 
exothermic cross - linking reaction , virtually undetectable . porated Barium Sulfate 
This may alleviate existing concerns with current injectable 35 CTAB was dissolved in 70 ml H2O for 30 minutes . 
polymers of damaging surrounding neural and vascular Ammonium hydroxide was added and the mixture was 
structures . stirred vigorously for 1 hr . TEOS and Barium Sulfate ( 70 
FIG . 9 presents temperature profile of PPF cross - linking mol % TEOS ) ( optional ) was added and stirred for 4 hr . The 
with varying alginate porogen content . Calcium alginate solution was centrifuged at 13 , 000 rpm for 10 min and 
beads were synthesized by emulsion / internal gelation meth - 40 washed in a mixture of ethanol and water several times . The 
ods described above without the addition of cells . The particles were dried under vacuum overnight at room tem 
change in temperature of the scaffold during cross - linking p erature . The surfactant was removed by placing the dried 
was measured by recording the temperature of the mixture particles in 100 ml ethanol and 1 ml concentrated HCl for 6 
as a function of time after the addition of the last component . hours . The solution was centrifuged at 13 , 000 rpm for 10 
The mixture was packed into a Teflon cylindrical mold 45 min and washed in a mixture of ethanol and water several 
( According to ISO5833 for acrylic resin cements ) where a times . This washing process allows for removal of surfactant 
temperature probe connected to a multimeter was positioned and the survival of the oxidized , active surface . The molar 
at the center of the mold to record the temperature of the ratio of the reaction was 100 TEOS : 29 CTAB : 35 , 700 H , O : 
mixture every 1 second until the temperature began to drop 714 NH3 - HO ( varies with desired size / aspect ratio ) . Size 
and then stabilize . 50 and morphology were characterized by dynamic light scat 
Controlled Release of Growth Factors from Platelet Rich t ering ( DLS ) transmission electron microscope ( TEM ) , and 
Plasma to Induce Cell Migration , Proliferation and Differ scanning electron microscope ( SEM ) . Surfactant removal 
entiation was characterized through zeta potential and FTIR . Pore size 
Alginate beads with platelet - rich plasma were fabricated and volume were observed through BET . The results are 
and separated into three size ranges using various sieves 55 summarized in Table 2 below and depicted in FIGS . 11A 
( x < 212 um , 212 < x < 500 um , and x > 500 um ) . 100 mg of 11C and FIGS . 14 - 16 . 
swelled alginate beads of each size range were weighted out 
into eppendorf tubes and 200 ul of DMEM was added to TABLE 2 
each sample . Samples were then placed horizontally on a 
rotator at 37 degrees Celsius . At various time point samples 60 Increase in aspect ratio and decrease in size 
through adjustment of TEOS , CTAB and Ammonia . were spun down ( 2500 rpm for 5 min ) and 100 ul of 
supernatant was removed from each sample and stored at CTAB HO NH3 TEOS 
- 20 C for later ELISA analysis . 
0 . 4 ( 567 mg ) 1000 ( 70 ml ) 20 ( 3 . 03 ml ) 2 . 8 ( 2 . 41 ml ) The release of PDGF , VEGF , and RANTES from PRP 0 . 8 ( 1134 mg ) 1000 ( 70 ml ) 20 ( 3 . 03 ml ) 2 . 8 ( 2 . 41 ml ) with alginate porogens of varying sizes is demonstrated in 65 3 0 . 4 ( 567 mg ) 1000 ( 70 ml ) 10 ( 1 . 51 ml ) 0 . 7 ( 0 . 6025 ml ) 
FIG . 10A . The effect of the mitogenic growth factors , 
PDGF - AB / BB / AA on cell proliferation is demonstrated in 
1 
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Protocol for Synthesis of Silica Nanoparticles with the than 90 % similarity of viability compared to the control cells 
Incorporation of Acrylate Surface Modification for Better in not incubated with silica nanoparticles . 
Corporation into Polymer Matrix Next , contrast agents were incorporated to enable the moni 
Nanorods were also synthesized in the same manner with toring of the scaffold degradation and tissue infiltration . 
the inclusion of 3 - ( trimethoxysilyl ) propyl methacrylate ( 3 . 5 5 X - Ray Detection of Barium Sulfate in Loaded Silica 
mol % TEOS ) with TEOS and Barium Sulfate . The molar Agarose scaffolds containing Barium Sulfate loaded silica 
ratio of the reaction was 100 TEOS : 14 CTAB : 142 , 000 of 0 , 2 . 5 and 5 % silica were prepared . Low melt agarose 
H , O : 1428 NH3 - H , O . The results are illustrated in FIGS . ( 2 . 3 % ) was mixed with barium sulfate loaded silica dis 
11A - 11C . persed in 400 ul of H2O . The mixture was subsequently Protocol for the Post - Synthesis Modification of Silica 10 loaded into cylindrical molds ( 6 mmx20 mm ) and placed in Nanorods ice for one hr . The agarose rods were place in a high 20 ul of millipore water was added to 1 mg of particles 
and sonicated for 10 minutes . A solution of 2 . 04 % acrylate resolution X - ray and read at 85 kV to show the ability to track silica and scaffold degradation through imaging . FIG . silane and 3 . 06 % Millipore water ( optional percentages ) in 
IPA was prepared ( 980 ul ) . The solution was mixed at 35° C . 15 21 shows X - ray image of agarose composite with from right 
at 1300 RPM for 2 hours . After modification , the particles to left 0 % , 0 . 5 % and 2 % silica nanorods containing barium 
were centrifuged at 13000 rpm for 10 minutes . The super sulfate . FIG . 22 shows GIF ( Gatan Energy Filter ) image 
natant was then removed and replaced with 100 % anhydrous through TEM showing presence of barium and sulfur within 
IPA for washing . This step was repeated two more times . silica nanorods . 
The supernatant was then removed and the particles were 20 Protocol for Loading and Releasing Bioactive Agents into 
moved to a vacuum oven overnight at 60° C . The results are Silica Nanorods 
depicted in FIG . 13 . Weigh out 10 mg of dexamethasone and place into 
Characterization of Two Forms of Silica Synthesis and eppendorf tube . Add 20 ul of solvent and dissolve the 
Modification and Barium Incorporation dexamethasone . Add the dexamethasone solution to 1 mil 
SEM and TEM images of silica nanorods are presented in 25 ligram of particles . Disperse the silica in the solution and 
FIGS . 3A - 3D , FIGS . 11A - 11C and FIGS . 14 - 16 . Particle place in the thermomixer for 1 hour at 35° C . Centrifuge the 
morphology of these materials was determined by scanning particles and remove the supernatant and place it into a 
electron microscopy ( SEM ) using a ( FEI Quanta 400 ESEM labeled tube for loading amount determination . Dry par 
FEG ) . with 10 kV accelerating voltage and 0 . 005 nA of ticles . Wash particles before using . 
beam current for imaging . For transmission electron micros - 30 Controlled Release of Glucose , Antibiotics , and Anti 
copy ( TEM ) studies , a small aliquot was taken from a Inflammatory Drugs 
suspension of isopropal alcohol and placed in a lacey FIG . 23 is a graph demonstrating controlled release of 
carbon - coated TEM grid , which was pulled through the model drug , DOX - HCl , from silica nanorods . FIG . 24 is a 
suspension and allowed to dry in air . The resulting sample graph demonstrating controlled release of Cefazolin from 
was examined with a Philips model CM - 30 TEM operated 35 silica nanorods . Next , the porous silica nanorods were 
at 300 kV . dispersed within a polymer matrix . 
BET ( Brunauer - Emmett - Teller ) of silica nanorod pore Nanocomposite Fabrication 
size distribution is presented in FIGS . 19A - 19B . The median PPF was mixed in NVP in a 1 : 2 mass ratio . Silica 
pore diameter were measured using N , adsorption / desorp - nanorods ( co - condensated and post modified ) were then 
tion measurements in a Micromeritics ASAP 2000 BET 40 mixed into the polymer blend at loading concentrations of 
surface analyzer system . The data were evaluated using the 2 . 5 , and 5 wt % . The cross - linking initiator , bp , was prepared 
Brunauer - Emmett - Teller ( BET ) and Barrett - Joyner - Hal - in a 0 . 1 g / mL NVP solution and added to the composite 
enda ( BJH ) methods to calculate the size distribution . mixture at 0 . 5 wt % . Samples for compressive testing were 
Biocompatibility of Silica Nanorods prepared by pouring the nanocomposite mixture into Teflon 
Biocompatibility data for silica nanorods is presented in 45 molds ( 6 . 5 mm diameter , 40 mm length ) . Samples were 
FIGS . 20A - 20C . Acrylate modified silica nanoparticles were subjected to vacuum to remove air bubbles within the 
dispersed in complete media at a concentration of 0 . 01 polymer and then placed in the oven at 60 degrees . Once 
mg / ml . This media was added to MDA 231 cells and allowed dried , samples were cut using a diamond saw into compres 
to incubate for 8 and 24 hours . After incubation , the media sion testing bars of approximately 6 . 5 mm diameter and 13 
was removed and saved . The cells were then washed with 50 mm height . 
PBS twice , removed from the wells with trypsin , and placed Enhancing the Mechanical Properties of Polymer Matrix 
in the corresponding Eppendorf tube containing the original Through Incorporation of Silica Nanorods 
media . Additional fresh media was added to the tubes to stop Mechanical properties of solid nanocomposite samples 
trypsin activity . The tubes were then centrifuged in at 1 , 500 were determined by an 858 Material Testing System 
rpm for 4 minutes to remove the media . The cells were then 55 mechanical testing machine ( MTS System Corporation , 
washed with Annexin Binding Buffer and centrifuged at Eden Prairie , Minn . ) with a sample size of five for each 
1 , 500 rpm for 4 minutes to remove the buffer . The samples group ( except for comparison studies with mixed and silica 
were then stained with Annexin V conjugated with Alexa nanorod composites which were conducted with a sample 
Fluor 488 . Annexin V is a protein that attaches to phospha s ize of three ) . Compressive mechanical testing was con 
tidylserine on the outer surface of the cell only during 60 ducted in accordance with ASTM D695 - 95 . Cylindrical 
apoptosis . Staining with Annexin V conjugated with Alexa samples were placed between two plates as the cross - head 
Fluor 488 will cause apoptotic cells to be fluorescent . The lowered onto the sample at a constant rate of 1 mm / min until 
samples were then analyzed for viability using a flow failure . The cross - head was lowered at a rate of 10 mm / min 
cytometer . to the center of each specimen until failure . Force and 
Acrylate modified silica nanoparticles were assessed for 65 displacement measurements were recorded and converted to 
biocompatibility . The silica nanoparticles are biocompatible stress and strain based on sample dimensions . The compres 
at the concentration of 0 . 01 mg / ml as seen by the greater sive modulus was calculated as the slope of the initial linear 
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region of the stress - strain curve . Compressive fracture leasing nanoporous silicon enclosures ( NSE ) , bioactive PA , 
strength was calculated as the maximum stress applied prior MSC , and a nutrient rich cocktail of PRP prior to injection . 
to failure . Once injected , the physiological fluid will degrade the 
FIG . 25A shows stress offset of control , 2 . 5 % co - conden - porogen thereby releasing the contents into the surrounding 
sated silica nanorods ( CC ) and post - modified silica ( E ) . FIG . 5 environment and creating a porous structure . 
25B shows compressive modulus of 2 . 5 % co - condensated The alginate beads were combined with PPF to form a 
silica nanorods ( CC ) and post - modified silica when dis composite putty capable of in situ cross - linking after injec 
persed in PPF polymer . tion into a fracture site . While PPF cross - linking causes 
Enhancing Cell Viability Through the Controlled Release significantly less exothermic heating than PMMA , we 
of Glucose into the External Environment of the Scaffold . 10 supplemented the PPF phase with pre - cross - linked ( but still 
Glucose Lactam loading and release was determined as chemically viable ) PPF microparticles to serve as a “ heat 
follows . 18 . 81 mg of 2 - keto - D - glucose was weighed out and sink ” and minimize exothermic reactions in vivo . It was 
placed into an eppendorf tube . 250 uL of water was added found that by including pre - polymerized PPF particulates 
to dissolve the glucose ( final concentration : 75 . 24 mg / mL ) . into the putty , peak temperature reached only 10° C . above 
20 uL of the 2 - keto - D - glucose solution was added to 1 15 body temperature for a duration of 1 to 3 minutes ( FIG . 
milligram of particles . The silica was then dispersed in the 26C ) . The addition of 15 % pre - cross - linked PPF dampened 
solution and placed in the thermo - mixer for 1 hour at 35° C . the temperature increase by half . Peak temperature occurred 
The particles were then centrifuged . The supernatant was at 1 minute 45 seconds . An increase of 5 - 6° C . within the 
removed and placed into a labeled tube for loading amount bone is comparable to a fever and biologically acceptable . 
determination . The particles were then washed twice with 20 Mechanical testing that followed indicated no loss in com 
water - save the supernatants and dried for 1 hour in pressive strength due to using pre - polymerized PPF . 
lyophilizer To release the glucose lactam from the silica , the To test the compressive strength of the putty , PPF and 
particles were rotated and incubated at 35° C . and centri - PPF - alginate bead composite scaffolds were fabricated in 
fuged . The supernatant was removed at 1 hr , 2 , hr , 3 hr , 6 hr , cylindrical Teflon molds . It was observed that the addition of 
8 hr , 12 hr , 24 hr , 48 hr etc . 200 ul of fresh PBS was then 25 porogen beads significantly increased the compressive 
added to the particles and the particles were re - suspended modulus of the material compared to porous scaffolds and 
and placed back on the rotator at 35° C . The supernatant at closely matched that of trabecular bone , the intended tissue 
the different time points was then read through a spectro for regeneration ( FIG . 8A ) . 
photometer and measured against a standard curve of glu In sum , mesoporous silicon nanorods can incorporate the 
cose lactam to understand the quantity of glucose lactam 30 following five properties : 1 ) mechanical reinforcement of 
released . the polymer matrix ; 2 ) delivery of active agents , such as 
Enhancing the Osteoconductive Properties of Composite bioactive molecules ; 3 ) mineral deposition , 4 ) increase in 
Scaffold Materials cell viability and 5 ) provide imaging / monitoring capability 
FIG . 26A presents mineralization data showing increase through incorporation of imaging agents , such as contrast 
in Calcium and phosphate in the presence of silica . In the 35 agents into the porous silica nanorod . 
sample of the agarose substrate in osteogenic media , where 
silica nanoparticles are present , there was a higher amount Example 6 . Surface Functionalization of 
of calcium and phosphate deposited on the surface of the Mesoporous Particles for the Sustained Delivery of 
agarose compared to that of the control where the silica Antibiotics for Orthopedic Applications 
nanoparticles are not present ( FIG . 26B ) 
The present inventors discovered that functionalization of Example 5 . Development of Injectable Composite a surface of porous or mesoporous particle with a polymer 
Putty may provide for a sustained release of an active agent , such 
as a therapeutic and / or imaging agent , contained in the 
Simultaneously , we have developed an injectable scaffold 45 particle ' s pores . 
featuring in situ setting polymer matrices with alginate - bead 
based porogens . Through the use of porogens within the SUMMARY AND BACKGROUND 
putty matrix , the cells , and bioactive molecules loaded 
within degradable microparticles can be delivered slowly in Bacterial infection is one of the most common problems 
vivo by the degrading porogen while simultaneously creat - 50 after orthopedic implant surgery . If not prevented , bacterial 
ing pores of optimal size for tissue and blood vessel infil - infection may result in serious and life threatening condi 
tration . The porogen technique involves dispersing particles , tions , such as osteomyelitis , which has shown a great 
such as hydrogel microspheres in a matrix of scaffold necessitate for local antibiotic delivery systems in the treat 
material [ 7 ] . After the scaffold material hardens , a composite ment of infections . Mesoporous silicon ( MPS ) with antibi 
consisting of the porogen and polymer remains and com - 55 otics may be one of the relevant approaches for obtaining a 
plete dissolution of the porogen can occur in vivo over time . controlled drug release . To characterize MPS , surface 
The end result is a 3D porous scaffold . The porogens will charge , surface modification and size distribution , and in 
therefore serve three key functions : ( 1 ) provide immediate vitro antibiotic release from them were carried out . HPLC 
mechanical stability to the scaffold ( 2 ) protect and delivers and UV spectroscopy were used for the assay of two 
cells and biological molecules essential for accelerating the 60 different antibiotics : Cefazolin and Clindamycin sodium and 
regenerative process and ( 3 ) create pores within the scaffold the assays method were validated . MPS with 10 - 100 uL 
post - injection to invoke the infiltration of natural bone . The diameter having 200 nm in length obtained by etching 
porogens can be tailored to control the pore size and porosity technique and sorted by centrifugation are used in this study 
of the scaffold . The size of the porogen sphere determines as novel drug delivery . It has shown that surface modifica 
the size of the pores within the scaffold and the polymer to 65 tion of MPS leads to decelerating the release of the inte 
porogen ratio is what determines the scaffold ' s porosity . The grated antibiotics . As well , biodegradability of MPS in 
developed porogen will encapsulate the growth factor - re phosphate buffer saline ( PBS ) solution was demonstrated . 
40 
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Such antibiotic release from the MPS may provide more sedimented the micron and supra - micron fraction . The 
reliable antibiotic protection at a targeted site of a bone supernatants were transferred to Oak Ridge Teflon Centri 
defect . fuge Tubes , and centrifuged at 10Kxg RCF using a Beckman 
Despite particular treatment , open fractures ( broken bones Ultracentrifuge to sediment the sub - micron fraction . The 
in communication with the environment ) present high rates 5 supernatants were centrifuged again at 26Kxg RCF to 
of complications because of the risk of bacterial infections sediment the low sub - micron fraction , while the nanometric 
and chronic osteomyelitis that can threaten the viability of fraction remained suspended and kept in solution . After 
the limb and even the life of the patient . Standard care for centrifugation , fragments were fractionated into micron , 
open fractures requires irrigation , debridement , stabiliza sub - micron , low sub - micron , and nanometer ranges . We tion , and antibiotic therapy and often results in multiple 10 characterized each production lot by SEM verifying their procedures according to the severity of the wound and the compliance to the required standards . The fragments were onset of infections . [ 1 ] 
The lack of proper control over a drug release rate and oxidized in hydrogen peroxide solution . Particle Size Distribution target delivery area is a huge disadvantage for conventional 
drug tablets . Tablets tend to provide rapid and immediate 15 5 uL of resuspended 20 ml of Isopropanol mixture of MPS 
release of therapeutic agents and require more frequent and in solution was diluted in 10 mL double filtered Isotonic 
repeated dosages for maintaining therapeutic levels , causing solution , ultrasonicated for a few seconds , and subjected to 
unwanted fluctuations in drug amounts delivered to the inverting for few times before measurement to achieve well 
blood and tissue . In order to circumvent problems in drug mixing . MPS were then sized using a Beckman Mutisizer IV . 
adsorption , metabolism , and irregular concentrations and to 20 Triplicate analyses were made on each suspension , which 
optimize the therapy itself , a controlled release dosage is corresponded to a single batch . Results are expressed as the 
advantageous over conventional tablets . Biomaterials with mean MPS diameter ( mm ) of the three batches as a function 
nanoscale features have become increasingly popular as of volume ( % ) . 
controlled release reservoirs for drug delivery . Nanoscale MPS Surface Charge 
drug delivery systems may be able potentially tune release 25 5 uL of resuspended 20 ml of Isopropanol mixture of MPS 
kinetics , enhance availability and distribution over time , and in solution was washed and diluted in 1400 UL 10 mM 7 . 4 
minimize toxic side effects , thus increasing the therapeutic pH Phosphate buffer , ultrasonicated for a few seconds , and 
effect of a given drug . Localization , controlled release , and subjected to vortexing for 5 minutes to prevent aggregation . 
sustainability of drugs over long periods of time within the MPS were then analyzed using a Brookhaven Zeta potential 
body may be some of the challenges in the design of 30 analyzer . Triplicate analyses were made on each suspension , 
effective drug therapies . which corresponded to a single batch . Results are expressed 
Delivery systems able to release antibiotics over an as the mean MPS surface charge of the three batches . 
extended period of time may solve all these issues and MPS Surface Modification 
provide efficacious alternative solutions to the current The mesoporous silicon were transfer to premeasured 
approaches . The objective of this study is to prove that 35 ultra - centrifuge tubes . They were spanned down using 
MesoPorous Silicon ( MPS ) may be effectively used in Beckman Coulter Ultracentrifuge at 12000 RPM for 20 min 
combination with orthopedic implants and / or with scaffolds at 4° C . The supernatant of each vial was removed and stored 
for bone tissue engineering to reduce the onset of infections separately . The fragments were dried out using vacuum oven 
and to enhance the ability of bone to heal in a timely fashion . for approximately 2 - 4 hour depends upon volume of the 
MPS may offer significant advantageous properties for drug 40 fraction at 75 - 80° C . The mass of the dried fragments was 
delivery applications as it favorably extend drug pharma - measured before proceed to oxidation step . 4 mL of H2O2 
cokinetics , stability as well as bio - absorbability . were Added to each tubing and shaked for a few times by 
Biodegradable MPS with well - controlled shapes , sizes hand and left for 2 - 3 hours . Each sample was sonicated for 
and pores have been developed . [ 2 ] The size of the pores 1 - 2 minutes . The sonicated sample was placed in the oven 
may confine the space for the entrapment of the antibiotic of 45 set at 90° C . for 2 hours to be completely oxidized . Isopro 
choice while MPS surface chemistry may affect the stability panol alcohol ( IPA ) was added to cover 1 cm above the 
and duration of its interaction with the antibiotic . The size of height of the dried - out fragments level . The samples were 
the pores and the surface chemistry can be easily altered and washed 3x with IPA . 
controlled to tune release kinetics . The ability to load drugs Loading of Antibiotics 
within the porous matrix of the particle at room temperature 50 At room temperature ( 25° C . ) , the MPS samples were 
enabled the use of MPS also with sensitive compounds placed in a vacuum ( 10 - 4 Torr ) for approximately 20 - 30 min 
susceptible to temperature dependent degradation or inacti to rid nanopores of any trapped alcohol . The high concen 
vation . tration antibiotic solution loaded was 1 mg / mL of each 
Mesoporous Silicon Fabrication antibiotics ( from Sigma Aldrich ) . The samples were incu 
Porous silicon fragments were produced by fractionation 55 bated for 2 hours to allow sufficient time for the drug to fully 
of sonicated multilayer porous silicon films . The multilayers penetrate into pore structure and then the drug - loaded MPS 
were produced by anodic etch of a 100 mm p + + Si wafer in samples were washed two times with phosphate - buffered 
a 1 : 2 HF : Ethanol solution . A 5 A current was applied for 2 - 6 saline ( PBS ) , pH 7 . 2 ( GIBCO ) . 
s followed by a 2 A current for 20 s . The two step process Agarose Coated MPS 
was repeated for 30 cycles with a stop of 8 s in between each 60 5 mg and 10 mg of agarose ( Sigma ) were reconstituted 
cycle . Finally a release current of 7 A was applied for 5 s . into 1 mL of deionized water respectively and the well 
The wafer was rinsed in DI water and briefly sonicated in mixed powder was melted at 65 C for 20 minutes and cool 
isopropanol to detach the porous layer . The porous silicon down to 37 C . Then , 20 uL of agarose solution was added 20 
suspension in isopropanol was transferred to a glass bottle L of fragments loaded , suspended and sonicated . The 
and sonicated for 24 hours to reduce average fragment size . 65 samples were mix and stored in the thermo - shaker for 15 
Successive centrifugation steps fractionated the obtained min . The samples were centrifuged down ( 10 min ; 14000 
porous silicon fragments . Initial centrifugation at 4300 rpm rpm ; 37 C ) and the supernatant was collected while the 
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solution was still warm . Then , the samples were resus FIGS . 32 and 33 show FACS analyses of the MPS . FIGS . 
pended in deionized water and sonicated for few min . 34A - 34B present zeta potential of differently surface modi 
Gelatin Coated MPS fied MPS . 
All MPS were coated by modified hot - melt method . The Morphological Changes 
well - mixed gelatin powder was melted at 65 C and brought 5 To clarify the release mechanism , MPS morphology was 
to 37 C . The mixture was then diluted into two concentration studied by SEM during course of release . The images of 
solutions , and cooled at room temperature . The resulting MPS matrix loaded with antibiotics have been showing 
coated MPS were washed and dried in vacuum . significant dissolution of the drug due to the porosity and 
Release Studies surface degradation of the MPS matrix nanostructure which 
MPS samples were individually incubated in a humidified 10 can be tailored for some biomedical applications . 
95 % air / 5 % v / v CO2 incubator at 37° C . in 500 uL of fresh In our MPS delivery system and as it has been suggested 
PBS . At designated time points , 500 uL of the release by others , an active carrier system can sometimes be a part 
medium was exchanged and the antibiotic concentration was of an additional treatment in terms of contribution to the healing of the surrounding environment tissue . Another determined as described below . 15 benefit of silicon degradation byproduct is that it is non Quantification of Antibiotic Concentrations toxic . Cefazolin and Clindamycin are few examples of Both drugs have characteristic spectra by UV - VIS ( ultra common pharmaceutical antibiotics that reduce the bacteria violet and visible light ) absorption spectroscopy with peaks biofilm formation which were used as a model drug for this at 210 nm and 270 nm for Clindamycin and Cefazolin , study . 
respectively . With drug standards ranging from 1 to 200 20 Current advanced drug delivery improves delivery effi 
ug / mL , absorbance calibration curves obtained at these peak ciency and localization which may directly reduce pre 
wavelengths gave linear graphs with correlation coefficients scribed dosages to the patient . In medical practice , antibi 
greater than 0 . 98 . High performance liquid chromatography otics are given in large dosages but , controlled sustained 
( HPLC ) methods were used to further investigate Clindamy - release , would help reduce the toxic side effects , drug waste , 
cin and Cefazolin release from MPS . HPLC was performed 25 and additional complications . In addition , the sustained 
with a Hitachi chromatography system with LaChrom soft release from MPS may be tailored to provide the correct 
ware control . The chromatography system used a Agilent therapeutic dose to avoid adverse effects . Other properties , 
Technologies Zorbax Eclipse Plus C18 , a 50 - uL injection such as interactions between drug and matrix , pore size , pore 
volume , detection at 210 nm and 270 nm and a mobile phase geometry , and matrix reactions with surrounding media are 
was composed of 0 . 05M Monobasic Potassium Phosphate : 30 just a few other aspects needed to be considered for con 
Acetonitrile : Tetrahydrofuran ) ( 76 . 5 : 23 . 0 : 0 . 5 , V / v / v ) , at a trolled drug delivery system design . 
flow rate of 1 mL / min Calibration graphs were linear in the 
1 - 200 ug / mL concentration range . A relatively good resolu REFERENCES 
tion of Clindamycin peak from interferences was achieved at 
retention time between 1 . 3 - 1 . 5 min . 35 [ 1 ] Starr AJ . J Bone Joint Surg Am . 2008 February : 90 Suppl 
Scanning Electron Microscopy ( SEM ) Analysis 1 : 132 - 7 . 
MPS were observed by scanning electron microscopy . [ 2 ] Tasciotti E , Liu X , Bhavane R , Plant K , Leonard A D , 
Samples were washed with ethanol . Specimens were Price B K , Cheng M M , Decuzzi P , Tour J M , Robertson 
mounted on SEM stubs ( Ted Pella , Inc . ) using conductive F , Ferrari M . Nat Nanotechnol . 2008 March ; 3 ( 3 ) : 151 - 7 . 
adhesive tape ( 12 mm OD PELCO Tabs , Ted Pella , Inc . ) . 40 Epub 2008 March 
Samples were sputter coated with a 10 nm layer of gold [ 3 ] Chiappini , Ciro . , Tasciotti , E . , Fakhoury , J . R , Fine , D . , 
using a Plasma Sciences CrC - 150 Sputtering System ( Torr Pullan , L . , Wang , Y C , Fu , L . , Liu , X , Ferrari , M . J 
International , Inc . ) . SEM images were acquired under high ChemPhysChem . [ In Press ] . 
vacuum condition , at 20 kV , spot size 3 . 0 - 5 . 0 , using an FEI [ 4 ] Vallet - Regi M . 2006 . Chem Eur J 12 : 5934 - 5943 . 
Quanta 400 FEG ESEM equipped with an SE detector . 45 [ 5 ] Horcajada P , Ramila A , Perez - Pariente J , Vallet - Regi M . 
Results and Discussion 2004 . Micropor mesopor mater 68 : 105 - 109 . 
The release of antibiotics from non coated MPS was 
characterized by a 30 % burst within the first day ( FIG . 27 ) Example 7 . Agarose Surface Coating Influences 
and subsequent release of remaining antibiotics within 4 - 6 Intracellular Accumulation and Enhances Payload 
days . In contrast , surface coated MPS released only 10 - 15 % 50 Stability of a Nano - Delivery System 
within first day . Substantial release was completed within 6 
days . Bare MPS controls , without any surface modification , Protein therapeutics often requires repeated administra 
showed 60 - 70 % antibiotic release within 1 - 2 days as tions of the drug over a long period of time . Proteins ? 
expected . This proved that the nanostructures of MPS pores instability is a major obstacle to the development of systems 
were controlling the sustained drug release . This shape of 55 for their controlled and sustained release . In this work we 
release profile was similar for both antibiotics from MPS . describe a surface modification of nanoporous silicon par 
Nevertheless , a near sustain drug release was achieved over ticles ( NSP ) with an agarose hydrogel matrix that enhances 
5 - 6 days with an average release rate over all the time points their ability to load and release proteins , influencing intra 
was 400 - 500 ug . The desired release profile for many drugs cellular delivery and preserving molecular stability . 
would follow this type of sustained release so that the drug 60 We developed and characterized an agarose surface modi 
levels in the body remain constant while the drug is being f ication of NSP . Stability of the released protein after enzy 
introduced . matic treatment of loaded particles was evaluated with 
FIGS . 28 and 29 illustrate the accumulative release profile SDS - page and HPLC analysis . FITC - conjugated BSA was 
of Cefazolin within 5 - 6 days from MPS agarose and APTES chosen as probe protein and intracellular delivery evaluated 
coated , respectively . MPS matrix degradation over time was 65 by fluorescence microscopy . 
evaluated with flow cytometric analysis and multisizer We showed that agarose coating does not affect NPS 
analysis , as shown in FIGS . 30A - 30C and 31 , respectively . protein release rate while fewer digestion products were 
34 
cess . 
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found in the released solution after all the enzymatic treat This work describes a novel surface modification with 
ments . Confocal images show that the hydrogel coating agarose hydrogel developed to enhance protein stability 
improves intracellular delivery , specifically within the within nanoporous silicon particles ( NSP ) during sustained 
nucleus , without affecting the internalization process . and controlled release , and during enzymatic digestion . 
This modification of porous silicon adds to its tunability , 5 Moreover we report the coating ' s control over NSP intrac 
biocompatibility and biodegradability , the ability to preserve ellular trafficking and uptake . The enhancements to protein 
protein integrity during delivery without affecting release delivery of this NSP surface matrix coating may extend the 
rates and internalization dynamics . Moreover it may allow use of pSi as a versatile delivery system for enzymes , 
the silicon particles to function as protein carriers that enable vaccine antigens , and protein therapeutics in general . 
control of cell function . 10 Nanoporous Silicon Particles Synthesis and APTES 
During the last few decades protein therapeutics has Modification 
developed dramatically and gained a significant role in many NSP were designed and fabricated in the Microelectronics 
fields of medicine ( 1 ) . Proteins such as growth factors , Research Center at The University of Texas at Austin by 
hormones , and cytokines are achieving widespread recog - established methods ( 29 , 35 ) . In brief , after low pressure 
nition as therapeutic agents ( 2 ) , while protein epitopes are 15 chemical vapor deposition of 100 nm silicon nitride ( SiN ) , 
now being mapped and used for vaccination that provides photoresist was spun cast on a 100 mm , 0 . 005 12 - ?m p - type 
broad protection against infectious agents ( 3 ) . Various thera - Si wafer . A pattern consisting of 2 um dark field circles with 
peutic proteins have been proposed in the literature with a 2 um pitch was transferred to the photoresist by contact 
wide range of roles and functions in the body ( 4 - 7 ) : forma - photolitography . Then the pattern was transferred for 100 
tion of receptor domains on the cell surface , improvement of 20 nm into the silicon substrate by reactive ion etching with 
the intracellular and / or extracellular molecular transport , CFA gas . The photoresist was removed from the substrate for 
enzymatic catalysis of biochemical reactions , enzymatic or anodic etch preparation by piranha clean . The porous par 
regulatory activity , targeting , vaccines ( 8 , 9 ) and diagnostics ticles were formed by selective porosification through the 
( 10 - 12 ) . Protein drugs are able to act selectively on biologi - SiN mask by anodic etch . The SiN layer was removed by 
cal pathways but often require repeated administration , 25 soaking in HF , the substrate was dried and the particles were 
making their clinical use even more challenging than that of released in isopropanol by sonication . Particles were then 
conventional drugs ( 13 - 16 ) . The controlled and sustained oxidized by piranha ( solution of 2 : 1 vol . H2SO4 ( 96 % ) in 
release of proteins may enhance their therapeutic efficacy H2O2 ( 30 % ) ) for 2 h at 120° C . Then modified with 
and reduce the pain and inconvenience of frequent injec - aminopropyltriethoxysilane ( APTES2 % in IPA ) for 2 
tions . However , this route of administration faces a single 30 hours at 35° C . to provide a controlled positive charge to the 
major issue : protein instability ( 17 ) . Proteins are unstable particle surface that enhances protein loading capacity . 
molecules and once injected in the bloodstream they are Modification of Nanoporous Silicon Particles with Aga 
rapidly degraded and deactivated by specific enzymes ( 18 ) . rose Matrix 
Growth factors such as FGF and VEGF , for example , have Agarose coating was performed by suspending NSP in 
half - life as short as 3 and 50 minutes respectively ( 19 , 20 ) . 35 warm ( 40° C . ) agarose solution for 15 minutes and then the 
Furthermore sustained release ( days to months ) and formu - solution was cooled at 4° C . for 30 min . Agarose coating 
lation of the delivery system often exposes the protein to solutions were prepared at different concentrations ranging 
harmful conditions that disrupt its integrity and ultimately from 0 . 05 to 0 . 5 % , with low melt certified agarose ( BIO 
compromises its therapeutic efficacy ( 21 , 22 ) . RAD ) , used as received . To remove excess gel , particles 
In the past years , many drug - delivery systems have been 40 were washed with warm PBS ( 35° C . ) and cooled at room 
developed . Some organic ones ( e . g liposomes , micelles , temperature twice . Agarose coating of loaded NSP was 
nanoparticles ) are able to deliver drugs to a specific site and performed after loading before any washing step . 
at the desired rate ; yet , most of these systems are rapidly NSP Characterization 
eliminated by the reticulum endothelial system ( RES ) . Fur The volume , size and concentration NSPs were charac 
thermore , polymeric formulations ( such as PLGA ) , release 45 terized by a MultisizerTM 4 Coulter Counter ( Beckman 
acidic byproducts upon degradation , and can induce local Coulter ) . Before the analysis , the samples were dispersed in 
inflammatory responses that negatively impact protein the balanced electrolyte solution ( ISOTON VR II Diluent , 
integrity and activity ( 23 , 24 ) . Beckman Coulter Fullerton , Calif . ) and sonicated for 5 s to 
Porous silicon ( Si ) has been proposed as an ideal bio - ensure a homogenous dispersion . Their surface charge 
material for drug delivery thanks to its biocompatibility ( 25 , 50 before and after APTES modification and agarose coating 
26 ) , tunability of the porous structure ( 27 , 28 ) , ease and was measured in a PB buffer at pH 7 . 4 using a ZetaPALS 
versatility of processing through standard semiconductor Zeta Potential Analyzer ( Brookhaven Instruments Corpora 
technology ( 29 , 30 ) , and for the well established protocols tion ; Holtsville , N . Y . ) . The surface area and pore size 
for the optimization of its surface chemistry ( 31 , 32 ) . As a distribution of the NSPs were measured using N2 adsorp 
result , pSi has been successfully used to improve drug 55 tion - desorption isotherms on a Quantachrome Autosorb - 3B 
solubility , increase bioavailability , and modulate release Surface Analyzer . To prepare the sample , 10 mg of NSPs 
rates , thus paving a promising path for the realization of pSi was transferred to a sample cell , and dried in a vacuum oven 
drug delivery devices ( 33 - 35 ) . pSi has been successfully at 80° C . 
employed for the loading and release of peptides , proteins The sample was degassed at 200° C . for 12 hours , and the 
and nanoparticles in a controlled and sustained fashion 60 N2 adsorption - desorption isotherm was measured at 77K 
( 35 - 38 ) . Peptides loaded into porous silicon particles have over the relative pressure ( P / PO ) range of 0 . 015 - 0 . 995 . 
been systemically delivered in vivo resulting in a prolonged Nanopore size distributions and porosities were calculated 
effect compared to their free administration ( 39 ) . Post syn - from the desorption branch of the isotherms using the BJH 
thesis modification of pSi provided controlled release and model . NSP size and shape was also evaluated at different 
enhanced loading of bioactive molecules ( 33 , 36 , 37 , 40 ) . 65 timepoints during incubation in PBS at room temperature by 
However , the stability of the loaded / encapsulated protein scanning electron microscope ( SEM ) ( FEI Quanta 400 
has not been guaranteed thus far . ESEM FEG ) . To prepare SEM sample , a drop of PSN IPA 
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solution is directly placed on a clean aluminum SEM sample Cellular internalization of NSP and uptake of BSA were 
stub and dried . Ag samples were sputter - coated with gold for observed for both systems by confocal microscopy ( Leica 
2 min at 10 nm layer using a CrC - 150 Sputtering System MD 6000 ) after 24 and 48 hours incubation with Ag or NC 
( Torr International , New Windsor , N . Y . ) . All the samples particles . Cells were stained with fluorescent phalloidin 
were loaded in SEM chamber , and SEM images were 5 ( actin filaments ) and DRAQ5 ( nuclei ) after fixation in 4 % 
measured at 5 kV and 3 - 5 mm working distance using an paraformaldehyde . Cellular uptake of BSA from 1 mg / mL 
In - lens detector . Size variation over time was also examined BSA - FITC conjugated solution prepared in DMEM was also 
by fluorescence activated cell sorting ( FACS ) ( Becton Dick evaluated . All images used for quantification were acquired 
inson , FACSCalibur ) . Solution pH was measured with pH by keeping the same acquisition setting ( pinhole , gain , laser 
strips ( colorPHast — EMD ) . 10 power , optical path , line average , zoom and image resolu 
Protein Loading and Release tion ) for the whole duration of the experiment . Numerical 
Lyophilized and fluorescein isothiocyanate ( FITC ) con evaluation of the fluorescence was performed using the 
jugated bovine serum albumin ( BSA ) was chosen as a Nikon Elements software . The average fluorescence within 
protein probe , purchased from Sigma - Aldrich , and used as the cytoplasm or the nuclei was measured in different , 
received . BSA was loaded into NSP by suspending 108 NSP 15 representative field of views ( at least 5 cells per image per 
in 200 uL of 25 mg / mL BSA ( 1 . 2 % of BSA was FITC timepoint ) . Cellular uptake of BSA from protein dispersed in 
conjugated ) aqueous solution ( prepared in PBS GIBCO solution was not numerically quantified because by using the 
Invitrogen ) . The suspension was continuously mixed in dark same confocal setting most of the cells appeared supersatu 
at 4° C . for 2 hours , then spun down and the supernatant was rated thus not allowing a direct comparison between the two 
removed . To remove excess of probe three washing steps 20 conditions . 
were performed . Coated and not coated particles underwent Statistical Analysis 
the same number of washing steps . Reported data are the averages of at least three different 
To measure the loading efficiency of NSP , the fluores measurements , and statistical significance ( p < 0 . 05 ) was 
cence and concentration of the BSA solution used for the evaluated with ANOVA ( Origin ) , if not otherwise stated in 
loading ( as prepared for the loading procedure and as 25 the text . 
recovered after incubation ) , was quantified by spectrofluo - Characterization of Nanoporous Silicon Particles 
rimetry with SpectraMax M2 spectrophotometer ( Molecular NSP used in this work are quasi - hemispherical shells of 
Devices ) . The BSA loss during coating procedure was also 3 . 2 um diameter and 600 nm shell thickness ( FIG . 35A and 
taken into account by measuring coating and washing solu - FIG . 35F ) designed for drug delivery application ( 41 ) . Pore 
tions fluorescence / concentration . 30 size is 15 nm with 51 % porosity as estimated from the 
Protein release over time from NSP ( bare ( not coated - desorption branch of nitrogen adsorption / desorption iso 
NC ) and agarose coated ( Ag ) with two agarose concentra - therms . APTES modification altered particles ' surface 
tions ( 0 . 05 and 0 . 125 % ) ) , was studied by collecting all the charge ( zeta potential from – 23 mV to + 1 mV ) and allowed 
supernatants and replacing them with fresh PBS at each the loading of about 10 ug of BSA per million of NSP ( 7 ug ) . 
timepoint . Release quantification was performed measuring 35 BSA is negatively charged and could not be loaded in 
protein content in the supernatant with the Bradford method , oxidized particles ( loaded particle zeta potential was - 28 
by spectrofluorimetry and by FACS ( Becton Dickinson , mV ) . 
FACSCalibur ) . The agarose coating was developed and optimized to 
Protein Stability Analysis assure a protective function against harmful agents during 
NC and Ag ( 0 . 125 % ) NSP loaded with BSA , were treated 40 long - term release . SEM images ( FIGS . 35B - 35E ) indicated 
with trypsin ( 25 ug / mL ) for different times and enzymatic that the resulting agarose coating was uniform and density 
digestion was ended adding equal volume of bleaching increased with agarose concentration . Agarose hydrogel 
solution ( 20 % acetonitrile - CH3CN and 4 % trifluoroacetic matrix filled the pores and covered the particles ' surface 
acid - TFA in water ) at the different time points . The structural completely but did not alter appreciably the size and charge 
integrity of the BSA , released after 24 hours from NC and 45 of the NSP ( zeta potential was + 2 and - 30 mV for not loaded 
Ag NSP after the different trypsin treatments , was analyzed and loaded NSP respectively ) . 
with sodium dodecyl sulfate polyacrylamide gel electropho Agarose coatings appeared to be uniform and smooth for 
resis ( SDS - page ) using Criterion Tris - HCl Gel ( BioRad ) in all conditions considered . At the highest agarose concentra 
non reduced condition and high performance liquid chro - tions ( 0 . 25 and 0 . 5 % hydrogel residues and particle aggre 
matography ( HPLC ) ( ELITE LaChrome , Itachi ) . Digestion 50 gates appeared ( see supplementary information ) . To assure 
products were also quantified analyzing SDS page silver stable uniform coating and good dispersion of the particles , 
stained bars with Image ) . 0 . 05 and 0 . 125 agarose concentrations ( A1 and A2 respec 
Cell Culture and Confocal Microscopy tively ) were selected for further analysis , together with bare 
Human umbilical vein endothelial cells ( HUVEC ) were ( not coated — NC ) NSP for comparison . 
cultured in complete Dulbecco ' s modified eagle ' s medium 55 Degradation process of NC NSP as observed at SEM is 
( DMEM ) at 37° C . and in 5 % CO , using 2 different systems : shown in FIGS . 36A - 36H . 
( a ) 4 chamber tissue culture treated glass slides and ( b ) SEM images show the progressive degradation of NSP 
circular glass coverslip of 8 mm diameter placed in 12 well ( into orthosilicic acid as assessed by ICP , data not shown 
plates . 120 , 000 and 240 , 000 cells were seeded per chamber ( 35 , 42 , 43 ) ) during degradation while their size slightly 
and well respectively . Cells were allowed to settle for 2 60 decreased . Degradation rate of exposed silicon was uniform 
hours before adding NSP . On the glass slide 600 , 000 NC or across the entire particle . As previously reported , we 
Ag NSP loaded with BSA FITC - conjugated were added observed higher degradation in the outer rim because of the 
directly to the cells in each chamber and incubated for 24 higher surface area and porosity of this structure ( 42 ) . 
and 48 hours . In the multi - well plate 1 , 200 , 000 NC or Ag NSP degradation over time was also monitored with flow 
NSP loaded with BSA FITC - conjugated were added in a 65 cytometry ( FACS ) ( FIGS . 37A - 37N ) quantifying NPS size 
transwell over the cells to each well , avoiding direct contact variation through the change in the forward scattering inten 
between cells and NSP . sity . Polystyrene beads of given size were used as calibration 
30 
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standards . FACS data showed that NPS size reduced in three analysis and confirm the protective function of the agarose 
days from about 3 to almost 2 Om ( FIGS . 37A , 370 , 37H , coating from enzymatic digestion . 
and 37K ) as was observed also at the SEM . FACS analysis Cellular Internalization of NSP and Uptake of Protein 
reveals no significant differences between NC and Ag NSP Cellular uptake of protein was studied using fluorescent 
with either agarose concentrations ( A1 and A2 ) ( FIGS . 5 BSA and evaluating the fluorescence within HUVEC by 
37A - 37N and FIGS . 370 - 37P ) . confocal microscope imaging after 24 and 48 hours . Par 
Quantification of Protein Release ticles internalization and BSA uptake after 48 hours of 
To assess protein release from Ag NSP , fluorescent BSA incubation with NC and Ag ( composition A2 ) NSP added was used as model . Loading and release of BSA from Ag 
NSP with two agarose concentrations ( Al and A2 ) and NC 10 is shown in FIGS . 41A - 41F . into the media with the cells or in a transwell on top of them 
NSP were quantified by fluorescence spectroscopy . Loading After 48 hours of incubation with cells , both NC and Ag efficiency was about 70 % for both NC and Ag NSP ( FIG . NSP were completely internalized and BSA was released 38A ) ; hence the agarose coating did not affect protein within the cells . Confocal microscopy showed that the loading . FACS and spectrometric BSA release data are 
shown in FIGS . 38B and 38C respectively . 15 internalization process was not affected by the agarose 
FACS results ( FIG . 38B ) showed that NSP fluorescence coating and NSP accumulated in the lysosomes in less than 
exponentially decreased ( y = A * e * B * x - R2 > 0 . 91 ) in three 1 hour , as previously reported ( 44 ) . 
days . Moreover there was no significant difference between NSP internalization was inhibited using the transwells and 
NSP NC and Ag with both agarose concentrations . Spectro - BSA was first released in the media and then incorporated 
fluorimetry data ( FIG . 38C ) also showed that all the loaded 20 into the cells . Images show that uptake of BSA released from 
protein was released with a logarithmic profile ( y = A * 1n ( x ) + NSP in the transwell or from BSA solution was not uniform 
B - R2 > 0 . 98 ) within three days for NSP NC and Ag with both within the cells and the protein probably accumulated within 
agarose concentrations . FACS and spectrofluorimetry data the lysosomes . The fluorescence within the cells receiving 
agreed showing that while the BSA was released from NSP BSA from the transwell was comparable with that of the 
the particles ' fluorescence decreased accordingly ( see 25 cells that internalized NSP . The cellular uptake of BSA from 
supplementary information for fitting curves and param - protein dispersed in solution ( 1 mg / mL ) appears higher than 
eters ) ; after 3 days almost all BSA was released ( ~ 90 % ) and the one achieved by NSP release ( to avoid pixel oversatu 
NSP were almost not fluorescent anymore ( ~ 5 % ) . Protein ration , different confocal settings were used to acquire FIG . release study results indicated that agarose coating does not 41F ) . 
affect protein release from NSP . This can be attributed to less BSA being released from Released Protein Integrity Analysis NPS resulting in a lower overall BSA concentration in the To assess the protection of protein integrity provided by media . A difference in the cellular uptake of BSA between agarose coating , BSA loaded NSP were treated with trypsin internalized Ag and not coated particles was observed . We for 10 , 30 , 60 and 120 minutes , and released BSA solution 
analyzed with SDS page . Resulting gel for NC and Ag 35 byp 35 . hypothesized that the agarose coating was able to induce a 
( composition A2 ) NSP is shown in FIG . 39A . change of pH within the lysosomes and influence the cellular 
The gel analysis showed several protein fragments , diges - uptake . To assess if the agarose coating matrix would affect 
tion products , together with BSA and trypsin ( when added ) , the pH within the lysosomes , different volumes of pH 5 
and no aggregates ( see supplementary information ) . The solution and agarose coating solution were mixed at room 
concentration and number of fragments appeared higher in 40 temperature and the change of pH was measured ( FIG . 42 ) . 
the solutions released from the NC NSP . Moreover the As shown in FIG . 42 , pH increased from 5 to 6 or more , 
presence of protein fragments increased with trypsin treat - depending on the ratio of agarose coating solution ( AG ) , 
ment time while trypsin and BSA amounts were about the while no change of pH was observed if agarose was prepared 
same in all the samples . with DI water instead of PBS . This experiment revealed that 
To better quantify protein , enzyme , and digestion prod - 45 the agarose solution used to coat the particles had a buffering 
ucts the SDS result was also analyzed with ImageJ and the capacity which could have been instrumental for the local 
three most abundant digestion products plotted as function modification of the pH in the small acidic lysosomal envi 
of trypsin treatment duration ( FIGS . 39B - 39D ) . The quan ronments . 
titative analysis showed that solution recovered from NC The progression over time of the uptake process relative 
NSP samples contained a higher concentration of digestion 50 to HUVEC incubated with NC and Ag NSP is shown in 
products than the one recovered from Ag NSP for all FIGS . 43A - 43D . After 24 hours of NSP incubation , cellular 
treatment conditions . The samples not treated with trypsin uptake of BSA was visible but still not evident especially for 
showed no difference between NC and Ag NSP . The amount NC NSP . BSA accumulated in the cells where the NSP , both 
of BSA and trypsin was the same in all treated samples . The NC and Ag particles , were internalized . The protein , escap 
amount of fragments increased with trypsin treatment time 55 ing from the lysosomes , was uniformly distributed through 
for the NC NSP samples but was almost constant in the Ag out the nuclei and the cytoplasm of the cells . We hypothesize 
NSP ones . that the agarose coating affected lysosome pH once NSP 
HPLC analysis performed on BSA solution recovered after were internalized and hence facilitated protein escape . 
24 hours from NSP not treated and treated with trypsin for To better quantify the BSA uptake within the cells , the 
15 minutes , 2 hours , 4 hours , 8 hours and 18 hours is shown 60 average green fluorescence intensity of confocal images 
in FIGS . 40A - 40B . within the cytoplasm and the nucleus of the cells was 
Graphs show an increase of digestion products concen quantified with Elements ( Nikon ) and correlated with the 
tration and number with duration of trypsin treatment . There number of NSP internalized in each cell ( FIGS . 43E - 43F ) . 
were more digestion products in the solution released by NC Data showed a higher uptake of BSA within cells incubated 
particles especially for longer trypsin treatment time , as 65 with Ag NSP than with NC NSP . Uptake of the protein was 
evidenced especially for the three species pointed by the also proportional to the number of particles internalized . 
arrows . These results are in agreement with the SDS - page Uptake of BSA released from Ag NSP increased more 
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rapidly with the number of internalized NSP than from NC 8 . W . Szmuness . Hepatitis B vaccine : demonstration of 
NSP . Additionally protein accumulated within the nuclei efficacy in a controlled clinical trial in a high - risk popu 
more than within cytoplasm . lation in the United States . N Engl J Med . 303 : 833 - 841 
These data suggested that agarose coating increases cellular ( 1980 ) . 
uptake of the protein and avoids extended entrapment in the 5 9 . L . Shi . Gardasil : prophylactic human papillomavirus 
lysosomes . vaccine development [ mdash ] from bench top to bed - side . 
Conclusion Clin Pharm Ther . 81 : 259 - 264 ( 2007 ) . 
In this work we successfully modified with hydrogel NSP , 10 . D . B . Sodee . Multicenter ProstaScint imaging findings in 
designed and fabricated for drug delivery application , to 2154 patients with prostate cancer . Urology . 56 : 988 - 993 improve their efficacy for intracellular protein release . We 10 02000 ) 
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37 . C . A . Prestidge , T . J . Barnes , A . Mierczynska - Vasilev , W . engineering and drug delivery in virtue of its biodegradable 
Skinner , F . Peddie , and C . Barnett . Loading and release of 50 and biocompatabile nature . [ 1 ] As a scaffold , pSi is suitable 
a model protein from porous silicon powders . physica for directing the growth of neuronal cells 4 ) and for stimu 
status solidi ( a ) . 204 : 3361 - 3366 ( 2007 ) . lating mineralization in bone tissue engineering . [ 3 , 4 ] For 
38 . R . E . Serda , B . Godin , E . Blanco , C . Chiappini , and M . therapeutic delivery , pSi has been administered orally , [ 5 ] 
Ferrari . Multi - stage delivery nano - particle systems for intravenously , [ 6 ] or been injected percutaneously and intra 
therapeutic applications . Biochimica et Biophysica Acta 55 peritonealy in humans for brachytherapy without notable 
( BBA ) General Subjects . In Press , Corrected Proof : in side effects . [ 7 ] A wide variety of therapeutic and imaging 
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39 . M . Kilpelainen , J . Riikonen , M . A . Vlasova , A . Huotari , pSi particles including steroids , [ 8 ] hormones , 19 ) proteins , [ 10 ] 
V . P . Lehto , J . Salonen , K . H . Herzig , and K . Järvinen . In cancer drugs , [ 111 iron oxide nanoparticles , [ 12 quantum dots , 
vivo delivery of a peptide , ghrelin antagonist , with mes - 60 liposomes 13 ) and carbon nanotubes 14 , 15 ) showing the great 
oporous silicon microparticles . Journal of Controlled versatility of this material as a delivery system . Also , the size 
Release . 137 : 166 - 170 ( 2009 ) . and shape as well as the porosity and pore size of the pSi 
40 . E . J . Anglin , M . P . Schwartz , V . P . Ng , L . A . Perelman , particles can be engineered and tightly controlled during 
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and Release of a Steroid . Langmuir . 20 : 11264 - 11269 and to control degradation time and kinetics as well as 
( 2004 ) . biodistribution and bioaccumulation . [ 16 ] Additionally , their 
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surface can be functionalized to accomodate various drugs , of FITC - BSA loaded microspheres . FIG . 46B shows the 
control cellular uptake , target specific tissues [ 17 ] and alter transmission microscopy image of the composite material 
their biodistribution in murine models , ( 13 , 18 ] thus allowing that allows to appreciate the pSi particles ( brown dots , see 
for the accumulation of therapeutic agents at tumor sites , [ 19 ] arrows ) embedded in the transparent spherical PLGA par 
or in reservoirs able to sustain the release of nanoliposomes 5 ticles . These images indicate that the pSi particles had been 
carrying siRNA . [ 20 ] fully encapsulated in the PLGA spheres . Fluorescent micros 
Also PLGA , an FDA approved biodegradable polymer , copy image ( FIG . 46C ) shows the same results . FITC - BSA 
has been widely investigated for drug delivery applications diffused from pSi particles into the PLGA layer . FIG . 46D 
due to a number of advantageous features . [ 21 , 22 ] First , its shows the size distribution of the PLGA / pSi microspheres . 
degradation rates can be tailored to obtain controlled deliv - 10 The microspheres displayed a distribution of sizes ranging 
ery of drugs . Secondly , the material properties can be from a few microns to approximately 35 um with an average 
adjusted by changing the lactic acid and glycolic acid ratio diameter of 24 . 5 + 9 . 54 um ( 145 microspheres were mea 
or molecular weight . Thirdly , PLGA nanoparticles or sured ) . 
microparticles can be formulated in order to load not only PLGA / pSi Microsphere Sorting 
small molecules but also proteins and larger payloads . [ 23 - 25 ) 15 PLGA / pSi microspheres prepared with 488 - DyLight con 
However , some issues that remain unsolved include the jugated pSi particles were characterized before and after 
achievement of a uniform , zero order , sustained , linear centrifugation sorting by fluorescence activated cell sorting 
release and to prevent the initial burst release typical of most ( FACS ) and confocal microscopy ( FIGS . 47A - 47E ) . FACS 
PLGA systems . [ 26 ] Additionally , the acidic PLGA degrada - data ( FIGS . 47A - 47B ) show that the mean fluorescence and 
tion by - products decrease the pH of the surrounding envi - 20 hence the percentage of coated particles increases of about 
ronment , which may cause undesired inflammatory one order of magnitude after centrifugation sorting . The 
responses . [ 27 ] Finally , the available fabrication methods for coated - fluorescent fraction was initially only the 10 % of the 
PLGA microparticles are incompatible with water - soluble sample and after the centrifugation process , it increased to 
proteins as they may degrade or denature at the organic / 80 % . Moreover the negligible fluorescence of the superna 
inorganic interface during formulation processes . [ 28 ] 25 tant reveals the absence of coated particles in it . Its mean 
In this study we show that the addition of pSi particles to fluorescence is two order of magnitude lower than the 
PLGA microspheres offers a solution to each one of the original sample and only 1 % of it has a comparable fluo 
aforementioned issues . pSi particles due to their high surface rescence ( FIGS . 47A - 47B ) . FIG . 47C shows the fluores 
area and to their interconnected pores allow for the storage cence intensity and distribution of 488 - DyLight conjugated 
and protection of large amounts of therapeutic molecules . [ 29 ] 30 pSi particles ( light green ) , nonsorted microspheres ( blue ) , 
Additionally , PLGA coating provides a tunable layer to seal sorted microspheres ( dark green ) , and supernatant solution 
pSi pores , slow down pSi degradation , and control the ( black ) . 
release of the payload . Orthosilicic acid , the by - product of Confocal images show a mix of fluorescent and not 
pSi degradation , 30 ) can neutralize the acidic pH of the fluorescent microspheres with polydistributed sizes in the 
PLGA degradation products thus creating less harsh and 35 not sorted sample ( FIG . 47D ) and a more uniform particles 
more cell friendly conditions in the microenvironment both size after the sorting procedure ( FIG . 47E ) confirming that 
in vitro and in vivo . [ 31 ] The use of hydrophilic pSi particles the sequential centrifugation procedure achieved a good 
increased the hydrophilicity of the PLGA / pSi system and separation of PLGA / pSi microspheres from smaller empty 
improved cell anchorage while not affecting cell prolifera - PLGA microspheres . 
tion . When the soluble proteins were efficiently loaded 40 Evaluation of FITC - BSA Loading 
within the pores of the pSi particles , their structural integrity The mechanism of loading and retention of the molecules 
( biostability ) was preserved . Furthermore , orthosilicic acid inside the pores of the pSi particles is based on the electro 
is involved in the collagen formation and facilitates the static interactions between the amino groups on the surface 
deposition of calcium and other minerals , thus stimulating of the APTES modified pSi particles and the carboxylic 
bone formation in orthopedic tissue enginereering applica - 45 portion of the amide groups in the protein . The loading 
tions . [ 32 , 33 ] efficiency of FITC - BSA into pSi particles varied between 
pSi Particles 9 . 77 % to 86 % , depending on the concentrations of the 
Quasi - hemispherical shaped pSi shells of 3 . 2 um in diam loading solutions ( data shown in supporting material ) . Dur 
eter and 600 nm shell thickness ( as shown in FIGS . 45A - ing the microemulsion step , the loss of the FITC - BSA was 
45D ) were fabricated according to established protocols . [ 14 ] 50 approximately 13 . 24 % , 9 . 84 % , and 5 . 14 % from the com 
Average Pore size was 20 nm with 51 % porosity as deter - posites and it inversely correlated with the density of the 
mined from the desorption branch of nitrogen adsorption different PLGA coatings ( 6 % , 10 % , and 20 % respectively ) . 
desorption isotherms ( data shown in supporting material ) . In This result demonstrated that during synthesis higher con 
order to turn the pSi surface from hydrophobic to hydro centrations of the coating solutions resulted in lower protein 
philic , the pSi surface was modified with ( 3 - Aminopropyl ) 55 loss . 
triethoxysilane ( APTES ) . Zeta potential analysis showed In Vitro Release of FITC - BSA 
that the surface charge of the particles after APTES modi The release profiles of FITC - BSA from pSi particles 
fication had a value of 6 . 44 mV , while the oxidized psi ( control ) , PLGA microspheres ( control ) and PLGA / pSi 
surface had a surface charge of - 30 . 39 mV . Once resus - microspheres are shown in FIG . 48A . In the case of pSi 
pended in IPA , the surface charge of the APTES modified 60 particles and PLGA microspheres ( 6 % , 10 % , and 20 % ) , 
particles showed no notable change for 2 weeks , thus protein release showed a massive initial burst release which 
indicating stable modification of the exposed silicon layer reached the plateau after less than 3 days . On the contrary , 
( data shown in FIGS . 56 - 58 ) . PLGA / pSi microspheres released approximately 70 % ( 6 % 
PLGA / pSi Microsphere Characterization PLGA ) , 38 % ( 10 % PLGA ) , and 25 % ( 20 % PLGA ) of the 
The overall aspect and the morphology of the micro - 65 payload at day 3 ( FIG . 48B ) . After 2 weeks , the release of 
spheres were characterized by optical , confocal , and scan - FITC - BSA from the composite reached approximately 
ning electron microscopy . FIG . 46A shows the SEM images 100 % ( 6 % PLGA / PSi ) , 60 % ( 10 % PLGA / PSi ) , and 40 % 
45 
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( 20 % PLGA / pSi ) of the payload as shown in FIG . 48C and BSA Stability Studies 
it continued to be released for other 2 weeks from the higher BSA , like all other proteins , is susceptible to hydrolytic 
density PLGA coatings ( 10 % and 20 % ) ( FIG . 48D ) . FIGS . degradation in aqueous solutions . These reactions can be 
49A and 49B show that at all time points , PLGA / pSi catalyzed by acidic molecules , such as the byproducts of 
microparticles showed consistently higher fluorescence 5 PLGA . In order to minimize protein degradation during 
when compared to controls . Due to the initial burst release loading , FITC - BSA was first loaded into pSi microparticles 
of FITC - BSA during the first 3 days , the fluorescence of and lyophilized prior to PLGA coating . This step reduces 
PLGA microspheres decreased at fast pace and dropped to exposure to water during particle preparation and during 
its minimum . Conversely , the addition of pSi particles to the eventual PLGA degradation . SDS - PAGE of released FITC 
PLGA microspheres reduced the FITC - BSA release rate as 10 BSA and degraded byproducts is exhibited in FIG . 52 . The 
demonstrated by the higher fluorescence intensity measured appearance of bands for degraded proteins is substantially less for PLGA / pSi - released BSA than controls at 7 days . throughout the experiment . Between 9 and 14 days , a relatively small amount FITC All together , the study of the in vitro release of FITC - BSA BSA is released which is insignificant compared to controls demonstrated that the PLGA coating played an important coating played an important 15 and 7 day time points . However , 10 % and 20 % coating 
role in controlling the release kinetics from the micro groups show only an intact FITC - BSA band and not small spheres . A higher concentration of PLGA resulted in a byproducts , indicating that molecules released after one 
coating layer characterized by higher density and thickness . week have not been hydrolytically degraded . This is likely 
As a consequence , the diffusion of FITC - BSA through the because molecules stored deep within the core of the 
PLGA layers was slowed down , resulting in lower release 20 microparticles are not exposed to any water until the PLGA 
rates and more sustained delivery of the payload . Similarly , coating has been sufficiently eroded . 
a thicker layer of PLGA delayed the degradation of the In Vitro Mineralization Studies 
composite microspheres thus additionally slowing down the PLGA microspheres do not calcify in the absence of 
release of the encapsulated proteins . In all profiles , the two bioactive materials which stimulate deposition of calcium 
phases observed during protein release were attributed to a 25 phosphate ( CaP ) bone mineral . This study has investigated 
minor fraction of the pSi loaded BSA which diffused into the if the addition of pSi microparticles to PLGA microspheres 
PLGA layer during the microsphere fabrication process and can render these inert microspheres bioactive . After incuba 
was released earlier than the fraction still loaded into the tion in the osteogenic media for 3 days , the smooth surface 
pores of pSi particles . of the PLGA / pSi microspheres was covered with a porous 
PLGA / pSi Microsphere Degradation 30 rough layer ( FIGS . 53A - 53G ) , while the control PLGA 
The PLGA / pSi microsphere degradation was studied by microspheres remained smooth with just minimal crystal 
monitoring the mophology changes using SEM . FIGS . 50A - deposition on the surface ( FIG . 53A ) . After 21 - day incuba 
50H and FIGS . 50J - 50P show the SEM images of three types tion , SEM images showed that the surface of PLGA / pSi 
of PLGA / pSi microspheres ( 6 % , 10 % , and 20 % PLGA microspheres was uniformly covered with a layer of mineral 
coatings ) degradation over 6 weeks in PBS . At week 1 , pores 35 deposites ( FIG . 53D ) while the control samples showed 
were observed on the surface of all three types of micro - negligible signs of calcification under the same conditions at 
spheres , showing an early - stage degradation . Pore number the same time intervals ( FIG . 53C ) . This phenomenon was 
and size increased with time and after 3 weeks , 6 % and 10 % confirmed at higher magnification at SEM ( FIG . 53E - 53F ) . 
PLGA / pSi microspheres appeared deformed and partially These data suggested that the pSi contained in the PLGA 
collapsed . At week 4 , more pores appeared on the surface of 40 microspheres has the ability to stimulate the formation of a 
the 6 % PLGA / pSi microspheres , while the surface layers of mineralized layer on the surface . As a confirmation of the 
polymer coatings were peeled off from the 10 % and 20 % formation of the calcium phosphate crystals on the surface 
PLGA / pSi mircospheres and a porous , sponge - like morphol - of the microspheres , in the EDX spectrum showed calcium 
ogy was observed beneath the surface . At week 6 , the 6 % and phosphorous peaks on the surface layer at day 3 ( grey 
PLGA / pSi microspheres completely lost their spherical mor - 45 dot line ) and day 8 ( black solid line ) ( FIG . 53G ) . The 
phology , while the 10 % and 20 % PLGA / pSi broke into mechanism of calcium phosphate deposition is that the 
pieces revealing the inner porous structure of the micro - polymerized silicic acid acted as heterogeneous nucleation 
sphere . substrate to stabilize the growing of calcium phosphate 
FIGS . 51A - 51B demonstrate the change of pH in the nuclei . The uniformly coated osteoactive mineral layer will 
medium during the degradation of PLGA , pSi , and PLGA / 50 further enhance the osteogenic qualities and the osteocon 
pSi microspheres . The control sample ( pSi ) kept a constant ductive potential of the scaffolds , while still allowing the 
pH value of approximately 7 . 2 during the 4 - week degrada - release of the bioactive molecules due to the inherent 
tion . PLGA microsphere degradation induced a pH drop at porosity of the surface mineralization ( see FIG . 9 ) [ 33 ] 
two weeks ( FIG . 51A ) . However , when pSi microparticles PLGA / pSi Microsphere Internalization by BMSCs 
were introduced to the PLGA microspheres , the pH values 55 Most growth factors and differentiating stimuli function 
recorded were approximately around 7 over the four - week by binding to cell surface receptors to start active transmem 
degradation period , and only the microspheres with the brane signal transduction while the ligand is still in the 
thickest coating ( 20 % PLGA ) generated acidic conditions extracellular space . When growth factors or differentiation 
after four weeks ( FIG . 51B ) . This is due to the fact that the stimuli are vehicled by a nanosized carrier and the carrier is 
pSi degradation product , silicic acid buffered the pH at 60 internalized by the target cells , they fail to interact with the 
higher values . 134 , 35 ] The mass ratio of PLGA to pSi is 5 : 1 membrane receptors and hence , completely lose their func 
( 6 % PLGA / pSi ) , 8 : 1 ( 10 % PLGA / pSi ) , and 16 : 1 ( 20 % tion and bioactivity . [ 36 ] The intended function of our com 
PLGA / pSi ) . The PLGA and pSi particles degrade concur posite particles is to release bioactive proteins at the site of 
rently , which allows silicic acid to buffer the acidic envi - tissue repair . In these scenarios , macrophages and other 
ronment when the acidic products of PLGA are produced . As 65 inflammatory cells often internalize and degrade nano 
expected , lower ratios showed higher buffer capacity than size particles through endocytosis , pinocytosis and phago 
the higher ratio . cytosis . [ 37 , 38 ] In this study , BSA was used as a moel growth 
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factor to be delivered by PLGA / pSi microspheres . The spheres can be used as tunable carriers for releasing bioac 
PLGA coating around pSi particles prevents internalization tive proteins to cells in a controlled and predictable fashion . 
due to its size , while providing a hydrophobic barrier to Conclusions Conclusions 
enzymes released by the cells thus protecting for longer A novel class of PLGA / pSi microspheres was fabricated 
times their bioactive payloads . One of the purposes of this 5 by an S / O / W emulsion method by incorporating polymer 
study was to determine if the PLGA / pSi microspheres could science with micro - litography and electrochemical etching . 
serve as potential vehicles to successfully deliver growth This system provides a number of unique advantages over 
factors . Confocal microscopy images showed that the 10 % pre - existing drug delivery materials thanks to its ability to : 
PLGA / pSi microspheres ( average diameter 24 . 5 um ) were 1 ) prevent the burst release of proteins and prolong the 
not internalized by the cells after 0 . 5 h ( FIGS . 54D and 10 delivery rate over a longer period of time through the tuning 
54G ) , 48 h ( FIGS . 54E and 54H ) and 120 h incubation of the PLGA coating ; 2 ) counteract the acidification of the 
( FIGS . 54F and 541 ) . The control images showed accumu environment by PLGA degradation byproducts via buffering 
lation of the uncoated pSi ( ~ 3 micron ) inside the bone with degradation products of the pSi particles ; 3 ) preserve 
marrow stromal cells within an hour from the beginning of protein stability and half - life as the S / O / W method prevents 
the incubation ( FIG . 54A , 30 min incubation ) and after 48 h 15 protein degradation during the fabrication process ; 4 ) con 
( FIG . 54B ) and 120 h incubation ( FIG . 54C ) . No cell death , trol cellular internalization and protein accumulation by 
morphological changes or overall cytotoxicity to BMSCs increasing the particle diameter with PLGA coatings and 
was observed in vitro during the entire cell culture period , controlling biomolecular release based on PLGA properties , 
confirming the compatibility of these composite micro - respectively . PLGA / pSi microspheres can not be internal 
spheres to cells and surrounding environment . FIG . 54J 20 ized by cells due to their size , which is particularly important 
shows a cartoon describing the mechanism of action of the for the delivery of growth factors and proteins interacting 
pSi particles ( right side of the dashed line ) versus the with extracellular receptors . 5 ) stimulate mineralization by 
PLGA / pSi composite microspheres ( left side of the dashed promoting the deposition of calcium phosphate ions on the 
line ) . While pSi are internalized by BMSCs ( FIG . 54J ) , the particle surface . All together , these findings demonstrate that 
PLGA / pSi particles lay on the surface of the BMSCs avoid - 25 the PLGA / pSi microspheres show superior properties than 
ing cellular uptake ( FIG . 54J ) . traditional PLGA microspheres and represent a promising 
Furthermore , the internalization of the pSi inside the cell alternative as drug delivery vehicles for tissue engineering 
would inevitably result in its entrapment into the lysosomal applications . Their use has been already successfully tested 
compartment as shown in FIG . 54 ) . The acidic environment in different orthopedic tissue engineering applications in 
of lysosomes would denature the growth factors , affect their 30 small and large animal models of bone fracture repair 
bioactivity and natural site of action thus resulting in the ( manuscript in preparation ) . 
complete absence of a response to the treatment ( FIG . 
54J ) . 139 , 40 ] On the contrary , the ability of the PLGA / pSi EXPERIMENTAL 
microspheres to escape internalization results in the double 
advantage of preventing the exposure of the payload to the 35 pSi Particle Fabrication : 
hostile lysosomal environment while releasing it in close The pSi particles were fabricated as previously described . 
contact to the external layer of the cellular membrane where [ 29 ] Briefly , an layer of silicon nitride ( SizN _ ) ( 80 nm ) was 
most of protein mediated signaling starts . As a consequence deposited by low pressure chemical vapor deposition on a 4 " 
of membrane receptor triggering , the signal pathway arrives p - type Si wafer with resistivity < 0 . 005 . AZ5209 photoresist 
to the nucleus thus allowing for a change in cell functions 40 ( AZ Electronic materials ) was spun cast at 5000 R . P . M . for 
( color change in FIG . 54J ) . 30 s on the substrate , followed by pre - exposure baking at 
Cellular Uptake of FITC - BSA Released from PLGA / pSi 90° C . in an oven for 10 min . A pattern consisting of dark 
Microspheres field circles ( 2 um ) with pitch ( 2 um ) was transferred on the 
BSA , like many growth factors , is internalized through photoresist with a MA / MB6 mask aligner . The pattern was 
receptor - mediated endocytosis ( clathrin - mediated endocyto - 45 developed for 20 s in MIF 726 developer , and then trans 
sis ) and fluid phase endocytosis , 141 - 46 ] and was selected as a ferred into the silicon nitride ( Si N2 ) layer and 300 nm into 
model protein for the release and cellular uptake studies . As the silicon substrate by two step Reactive Ion Etch ( first step : 
mentioned previously , BSA released from PLGA / pSi micro - Plasmatherm 790 , 25 sccm CF4 , 200 m Torr , 250 W RF , 2 
spheres first activated cell surface receptors to start signal min 20 ; second step : Oxford Plasmalab 80 , 20 sccm SF , 
transduction to alter intracellular response and then BSA 50 100 m Torr , 200 W RF , 4 min ) . The photoresis was removed 
was internalized by the cells ( FIG . 54J ) . To assess the rate from the substrate by an 8 min piranha clean ( H , O , : H , SO . 
of cellular uptake of the BSA released from the PLGA / pSi 1 : 2 v / v ) . The porous particles were formed by anodic etch in 
microspheres , human umbilical vein endothelial cells ( HU - Hydrofluoric acid ( HF ) : ethanol ( 1 : 3 v / v ) applying a current 
VEC ) were studied using confocal microscopy after 7 days ( 0 . 3 A ) for 60 s followed by 3 . 8 A for 6 s in a custom Teflon 
in culture . HUVEC cells were plated in a transwell without 55 etching cell . The SizN _ layer was removed by soaking in HF 
microspheres and incubated with PLGA / pSi in the top for 30 min , the substrate was dried and the particles were 
chamber ( FIGS . 55A - 55E ) . Confocal images show an evi - released in isopropanol ( IPA ) ( Acros ) by sonication . 
dent cellular uptake of BSA after 7 days of incubation with Z2 Analysis and Surface Modification of pSi : 
PLGA / pSi microspheres . Cellular uptake appeared in dis - For oxidation , the dried pSi particles were resuspended in 
crete spots that probably suggesting protein accumulation in 60 a piranha solution and heated to 110 - 120° C . for 2 h . The 
subcellular organelles . The control group ( BSA in solution ) suspension was washed with DI water until the pH was 
did not show any BSA accommulation in cells . Fluorescence approximately 5 . 5 - 6 . 0 . Oxidized pSi particles were sus 
quantification of the confocal images showed 35 fold pended in ISOTON® II Diluent , and counted by a Multisizer 
increase of the corresponding green fluorescence , while no 4 Coulter® Particle Counter ( Beckman Coulter ) with an 
difference was recorded in the red and blue fluorescence 65 aperture ( 20 um ) . PSi particles were surface modified with 
associated to the cytoscheleton ( actin ) and nucleus ( blue ) APTES ( Sigma Aldrich ) as reported previously . [ 16 ] 1x108 
respectively . These results suggest that PLGA / pSi micro oxidized particles were suspended in of Millipore water ( 20 
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ul ) . A solution was prepared of 2 . 0 % APTES and 3 . 0 % ( Becton Dickinson , FACSCalibur ) before and after sorting 
Millipore water in IPA . This solution ( 980 ul ) was added to procedure to assess sorting efficiency . 
the particles and mixed well . This vial was placed to a 35º Evaluation of FITC - BSA In Vitro Release : 
C . thermomixer set to mix at 1300 rpm for 2 h . After 2x10 ' FITC - BSA loaded PLGA / pSi microspheres were 
modification , the particles were washed with anhydrous IPA 5 dispersed in PBS ( 1 ml ) at 37° C . At predetermined time 
5 times and moved to a vacuum oven for annealing at 60° C . intervals , the suspension was centrifuged ( 4500 rpm ; 5 min ) , 
overnight . and the supernatant ( 1 ml ) was collected , and replaced with 
Loading of FITC - BSA into APTES Modified pSi Par fresh PBS ( 1 ml ) . The amount of BSA released was deter mined by analysis of the collected supernatant using a ticles : 
FITC - BSA ( Sigma Aldrich ) solution ( 10 mg / ml ) was as 10 spectrophotometer at 493 / 518 nm . The suspension was also analyzed by FACS and the samples were prepared by mixing prepared by dissolving FITC - BSA powder in distilled water . 
4x108 APTES modified particles were immersed into of NaCl solution ( 150 ul ) with suspension ( 5 ul ) removed from in vitro release samples . FITC - BSA solution ( 200 ul ) in an eppendorf tube . The Degradation Studies : 
suspension was incubated on a thermal mixer at 37°C . under 15 The in vitro degradation of the PLGA / pSi microspheres 
agitation for 30 min to allow the adsorption of the protein was investigated by monitoring the surface morphology of 
into the pores of pSi particles . The particles were separated the microspheres and the pH of the degradation media . The 
by centrifugation and washed with PBS to remove the pH level was monitored using a pH meter ( Denver Instru 
FITC - BSA physically absorbed on the surface . The FITC - ment UB - 10 ) , and the surface morphology of the micro 
BSA loaded particles were then lyophilized overnight . The 20 spheres was examined by SEM . 
amount of protein absorbed was measured by the difference BSA Stability Studies : 
between the protein concentrations of the stock solution and SDS - PAGE gel electrophoresis was performed to deter 
of the supernatant using SpectraMax M2 spectrophotometer mine the hydrolysis of BSA during the FITC - BSA release 
( Molecular Devices ) . from PLGA / pSi . Color Silver Staining Kit was used to stain 
Preparation of PLGA Particles and PLGA Coated pSi 25 the gel , Mark 12 ( Invitrogen ) was used as standards . Super 
Particles : natant ( 100 ul ) released from PLGA / pSi microspheres ( 6 % , 
pSi particles coated with PLGA were prepared by a 10 % , 20 % ) collected on day 7 and day 14 was filtered by 
modified S / O / W emulsion method [ 47 ] as shown in FIGS . Amicon Ultra - 0 . 5 ml centrifugal filter ( Millipore Ultracel - 3 
44A - 44D . Briefly , PLGA ( 50 : 50 ) ( Sigma Chemicals Co . St . Membrane , 3 kDa ) before SDS - PAGE . 
Louis , Mo . ) was dissolved in dicholoromethane ( DCM ) 30 In Vitro Mineralization Studies : 
( Sigma Aldrich ) to form 6 % , 10 % , and 20 % w / v PLGAI The osteogenic media were prepared by base media 
DCM solution respectively . 8x107 FITC - BSA loaded par - ( a - MEM media ) ( Invitrogen ) containing Fetal bovine serum 
ticles were suspended in these solutions ( 1 ml , 6 % , 10 % , and ( 20 % , FBS ) ( Invitrogen ) supplemented with L - glutamine 
20 % ) respectively by sonicating the mixture . The organic ( 1 % ) , sodium pyruvate ( 1 % , Invitrogen ) , penicillin / strepto 
phase containing the pSi was mixed with of Poly ( vinyl 35 mycin ( 1 % , Invitrogen ) , and osteogenic supplement . PLGA 
alcohol ) ( PVA ) ( Fisher Scientific ) ( 3 ml , 2 . 5 % w / v ) by PSi microspheres were immersed in osteogenic growth 
vortex mixing and sonication . The mixture was gradually medium . After 3 , 8 and 21 day incubation , the specimens 
dropped into water ( 50 ml ) containing PVA ( 0 . 5 % w / v ) . The were washed carefully with DI water , and dried under 
resulting suspension was stirred with a magnetic stir bar for vacuum overnight before characterization . PLGA micro 
2 h and the DCM was rapidly eliminated by evaporation . 40 spheres were used as control . The samples were analyzed by 
The PLGA / pSi microspheres were washed with distilled SEM coupled with energy dispersive X - ray ( EDX ) for min 
water . Finally , the product was lyophilized and stored at 4° eralization studies . 
C . PLGA particles were prepared in the similar method as In Vitro Internalization Studies : 
PLGA / pSi microsphere fabrication , except that BSA solu - 6 , 500 BMSCs were seeded into a 4 chamber tissue culture 
tion instead of BSA loaded pSi particles was mixed with 45 treated glass slides . When the cells were 30 % confluent , 
PLGA / DCM . PLGA / pSi microspheres containing 65 , 000 pSi particles 
Characterization of PLGA / pSi Microspheres : were added into each chamber . 65 , 000 pSi particles were 
The morphology of the microspheres was characterized used as control . After 0 h , 24 h , 48 h , and 120 h incubation , 
by optical microscope ( Nikon Eclipse TS 100 ) , fluorescent cells were washed with PBS and fixed with 4 % paraform 
microscope ( Nikon Eclipse TE 2000 - E ) , confocal laser 50 aldehyde ( PFA ) for 10 min at room temperature . PFA was 
microscope ( Leica MD 6000 ) , and scanning electron micro - removed and washed twice with PBS . Cells were permea 
scope ( SEM ) ( FEI Quanta 400 ESEM FEG ) . The samples bilized with 0 . 1 % Triton X for 10 min , and then blocked 
were analyzed by confocal laser microscope at 488 nm to with BSA ( 1 % ) in PBS for 30 min at room temperature . 
identify the FITC - BSA loaded pSi . The microspheres were Triton X was removed , and cells were incubated with Alexa 
also examined by SEM under a voltage of 3 KV . The 55 Fluor 555 conjugated phalloidin in BSA ( 1 % ) in PBS for 30 
samples were sputtered with gold ( 20 nm ) by a Plasma min Cells were washed and incubated with DRAQ5 for 1 h . 
Sciences CrC - 150 Sputtering System ( Torr International , DRAQ5 was removed and prolong gold was added on the 
Inc ) before SEM analysis . slides to mount the sample . 
Sorting Procedure : In Vitro Cellular Uptake of FITC - BSA : 
Several centrifugation steps , optimizing time and rotation 60 40 , 000 HUVEC were seeded and cultured on a glass 
rate of each step , were performed to separate the PLGA / PSi coverslip in a 12 well plate with 500 million PLGA / pSi 
microspheres from the empty PLGA microspheres . Separa - microspheres loaded with FITC - BSA in a transwell on top of 
tion was carried out by three centrifugation steps of 10 min the cells . The media were changed every 3 days . Cellular 
each at 500 , 1200 and 4500 rpm respectively with the uptake of FITC - BSA released from the PLGA / pSi micro 
Allegra X - 22 Centrifuge ( Beckman Coulter Inc . ) . PSi par - 65 spheres was observed by confocal microscopy staining cells 
ticles conjugated with DyLight 549 NHS - Ester ( Thermo with fluorescent phalloidin ( actin filaments ) and DRAQ5 
Scientific ) coated with PLGA were analyzed by FACS ( nuclei ) after fixation ( 10 % formaldehyde ) . 
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Confocal Microscopy Analysis : Chiappini , C . Lu , K . Matsuo , B . Godin , R . L . Stone , A . M . 
Detection of the FITC - BSA loaded pSi particles was Nick , G . Lopez - Berestein , A . K . Sood , M . Ferrari , Cancer 
based on autofluorescence using 488 excitation laser and the Res . 2010 , 70 , 3687 . 
cells were analyzed by using 561 and 632 excitation laser for [ 21 ] B . H . Woo , G . Jiang , Y . W . Jo , P . P . DeLuca , Pharm . 
pholloidin and DRAQ5 respectively . Images were acquired 5 Res . 2001 , 18 , 1600 . 
using a Leica MD 6000 upright confocal microscope [ 22 ] M . van de Weert , W . E . Hennink , W . Jiskoot , Pharm . 
equipped with a 63x oil immersion objective . Res . 2000 , 17 , 1 59 . 
[ 23 ] J . M . Chan , L . Zhang , K . P . Yuet , G . Liao , J . W . Rhee , 
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5201 T . Tanaka , L . S . Mangala , P . E . Vivas - Mejia , R . Nieves - 65 Without further elaboration , it is believed that one skilled 
Alicea , A . P . Mann , E . Mora , H . - D . Han , M . M . K . in the art can , using the description herein , utilize the present 
Shahzad , X . Liu , R . Bhavane , J . Gu , J . R . Fakhoury , C . invention to its fullest extent . The embodiments described 
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herein are to be construed as illustrative and not as con 6 . The method of claim 1 , wherein the bone defect 
straining the remainder of the disclosure in any way what comprises a bone fracture . 
soever . While the preferred embodiments have been shown 7 . The method of claim 1 , wherein the subject is a human 
and described , many variations and modifications thereof being . 
can be made by one skilled in the art without departing from 5 8 . The method of claim 1 , wherein the bone defect is 
the spirit and teachings of the invention . Accordingly , the selected from bone fractures , maxillofacial defects , and 
scope of protection is not limited by the description set out craniofacial defects . above , but is only limited by the claims , including all 9 . The method of claim 1 , wherein the polymer matrix equivalents of the subject matter of the claims . The disclo comprises an unsaturated biodegradable polymer . sures of all patents , patent applications and publications 10 10 . The method of claim 1 , wherein the polymer matrix is cited herein are hereby incorporated herein by reference , to selected from collagen , alginate , gelatin , polycaprolactone , the extent that they provide procedural or other details 
consistent with and supplementary to those set forth herein . poly ( lactic - co - glycolic acid ) ( PLGA ) , poly ( propylene 
What is claimed is : fumarate ) ( PPF ) or poly ( e - caprolactone - fumarate ) . 
1 . A method of treating a bone defect in a subject , wherein 15 11 . The method of claim 9 , wherein the unsaturated 
the method comprises : biodegradable polymer is poly ( propylene fumarate ) ( PPF ) . 
injecting into the site of the bone defect an injectable 12 . The method of claim 1 , wherein the porogen particles 
composition comprising : comprise at least one natural or synthetic biodegradable 
a biodegradable polymer matrix ; particle . 
at least one biodegradable reinforcing particle dis - 20 13 . The method of claim 1 , wherein the porogen particles 
persed in the biodegradable polymer matrix , comprise poly ( lactic - co - glycolic acid ) ( PLGA ) . 
wherein the at least one biodegradable reinforcing 14 . The method of claim 2 , wherein the hydrogel porogen 
particle is selected from the group consisting of particles comprise at least one of alginates , fibrins , and 
porous oxide particles and porous semiconductor gelatins . 
particles , and 25 15 . The method of claim 2 , wherein the hydrogel porogen 
wherein the at least one biodegradable reinforcing particle comprises alginate . 
particle provides mechanical stability to the bio - 16 . The method of claim 1 , wherein the porogen particles 
degradable polymer matrix ; and comprise at least one biocompatible vesicle . 
porogen particles dispersed in the biodegradable poly - 17 . The method of claim 16 . wherein the biocompatible 
mer matrix , vesicle comprises at least one of a liposome or a micelle . wherein the porogen particles comprise at least one 18 . The method of claim 1 , wherein the active agent active agent , and 
wherein the at least one active agent is contained or comprises stem cells . 19 . The method of claim 18 , wherein the active agent encapsulated within the porogen particles ; 
wherein a scaffold is formed in - situ from the composition 35 comprises mesenchymal stem cells . 
20 . The method of claim 4 , wherein the at least one in the body of the subject at the site of the bone defect , 
wherein the scaffold comprises at least the polymer biodegradable porous particle comprises a silicon porous particle . matrix and the porogen particles , and 
wherein the porogen particles degrade on the scaffold 21 . The method of claim 4 , wherein the at least one 
to release the at least one active agent and form pores 40 in biodegradable porous particle comprises at least one active 
within the scaffold . agent . 22 . The method of claim 21 , wherein the at least one 2 . The method of claim 1 , wherein the porogen particles 
comprise hydrogel porogen particles . active agent is selected from the group consisting of thera 
3 . The method of claim 1 . wherein the at least one active peutics , imaging agents , anti - inflammatory agents , antibiot 
agent is selected from the group consisting of therapeutics , 45 usics , proteins , platelet rich plasma , cells , degradation inducers 
imaging agents , anti - inflammatory agents , antibiotics , pro of porous particles , and combinations thereof . 
23 . The method of claim 4 , wherein a surface of the teins , platelet rich plasma , cells , degradation inducers of 
porous particles , and combinations thereof . biodegradable porous particle is modified with a biodegrad 
4 . The method of claim 1 , wherein the porogen particles able polymer . 
contain at least one biodegradable porous particle within the 50 24 . The method of claim 23 , wherein the biodegradable polymer is agarose . porogen particles . 
5 . The method of claim 4 , wherein the biodegradable 25 . The method of claim 23 , wherein the biodegradable 
porous particle facilitates or controls at least one of intrac intrac polymer is poly ( lactic - co - glycolic acid ) ( PLGA ) . 
ellular delivery of an active agent , bio - distribution of an of an 26 . The method of claim 1 , wherein the porogen particles 
active agent , stability of an active agent , and internalization 55 on 55 in the composition are in solid form . 
of the porous particle by cells or organelles . 
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